

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Multiple Chemical Sensitivity Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-072098
Article Type:	Protocol
Date Submitted by the Author:	27-Jan-2023
Complete List of Authors:	Hempel, Susanne; University of Southern California Danz, Margie; University of Southern California Robinson, Karen; Johns Hopkins Medicine, Division of Health Sciences Informatics Bolshakova, Maria; University of Southern California, Preventive Medicine Rodriguez, Jesus; University of Southern California Mears, Alanna; University of Southern California Pham, Cindy; University of Southern California Yagy, Sachi; University of Southern California, Preventive Medicine Motala, Aneesa; University of Southern California, Southern California Evidence Review Center Tolentino, Danica; University of Southern California Akbari, Omid; University of Southern California, Molecular Microbiology and Immunology Johnston, Jill; USC Keck School of Medicine
Keywords:	INTERNAL MEDICINE, Systematic Review, GENERAL MEDICINE (see Internal Medicine)

SCHOLARONE™
Manuscripts

Multiple Chemical Sensitivity Scoping Review Protocol

Susanne Hempel,¹ Margie Danz,¹ Karen A. Robinson,² Maria Bolshakova,¹ Jesus Rodriguez,¹
Alanna Mears,¹ Cindy Pham,¹ Sachi Yagyu,¹ Aneesa Motala,¹ Danica Tolentino,¹ Omid Akbari,³
Jill Johnston⁴

¹ Southern California Evidence Review Center, University of Southern California, Los Angeles,
USA

² Evidence-based Practice Center, Johns Hopkins University, Baltimore, USA

³ Molecular Microbiology and Immunology, University of Southern California, Los Angeles,
USA

⁴ Population and Public Health Science, University of Southern California, Los Angeles, USA

Corresponding author

Dr. Susanne Hempel; Southern California Evidence Review Center, University of Southern
California, Keck School of Medicine, 2001 N Soto Street, Los Angeles, CA 90033; USA;
susanne.hempel@med.usc.edu

Word count: 3,210

ABSTRACT

Introduction: Multiple Chemical Sensitivity (MCS) is characterized by reported adverse responses to environmental exposures of common chemical agents (e.g., perfumes, paint, cleaning products, and other inhaled or ingested agents) in low doses considered non-toxic for the general population. There is currently no consensus on whether MCS can be established as a distinct disorder.

Methods and analysis: The scoping review of the literature will be guided by five questions: How is MCS defined and how is it diagnosed? What methods are used to report prevalence and incidence estimates of MCS? What are the characteristics of the body of scientific evidence that addresses whether MCS is a distinct disorder or syndrome? What underlying mechanisms for MCS have been proposed in the scientific literature? Which treatment and management approaches for MCS have been evaluated in empirical research studies? We will conduct a comprehensive search in 14 research databases. Citation screening will be supported by machine learning algorithms. Two independent reviewers will assess eligibility of full text publications against prespecified criteria. Data abstraction will support concise evidence tables. A formal consultation exercise will elicit input from experts and stakeholders regarding the review results and presentation. The existing evidence about MCS will be documented in a user-friendly visualization in the format of an evidence map.

Ethics and dissemination: Determined to be exempt from review (UP-22-00516). Results will be disseminated through a journal manuscript and data will be publicly accessible through an online data repository.

Registration: The protocol is registered in Open Science Framework (osf.io/4a3wu).

1
2
3
4
5 (249 words)
6
7
8
9
10

11 Keywords

12
13
14
15 Multiple Chemical Sensitivity, Idiopathic Environmental Illness, Chemical Intolerance, Scoping
16 Review, Evidence Map
17
18
19
20
21
22
23

24 Strengths and Limitations

- 25
26
27
28 • The scoping review of the literature will be guided by five questions: How is MCS
29 defined and how is it diagnosed? What methods are used to report prevalence and
30 incidence estimates of MCS? What are the characteristics of the body of scientific
31 evidence that addresses whether MCS is a distinct disorder or syndrome? What
32 underlying mechanisms for MCS have been proposed in the scientific literature? Which
33 treatment and management approaches for MCS have been evaluated in empirical
34 research studies?
35
36
- 37 • We will conduct a comprehensive search in 14 multi-disciplinary research databases.
38 Citation screening will be supported by machine learning algorithms. Two independent
39 reviewers will assess eligibility of full text publications against prespecified criteria.
40
41
- 42 • Data abstraction will support concise evidence tables. A formal consultation exercise will
43 elicit input from experts and stakeholders regarding the review results and presentation.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The existing evidence about MCS will be documented in a user-friendly visualization in
4
5 the format of an evidence map.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Multiple Chemical Sensitivity (MCS) is characterized by reported adverse responses to environmental exposures of common chemical agents in low doses considered non-toxic for the general population. These may be solvents such as paint and cleaning products, odorants such as perfume and scented soaps, air pollutants such as cigarette smoke and smog, or materials such as new furnishings or new carpets. Symptoms are nonspecific, involve multiple organ systems, and may include nausea, dizziness, headache, abdominal pain, fatigue, and depression, among others.¹⁻³ Responses generalize from individual to sets of often unrelated chemical agents and limit social and occupational functioning.^{2 4-8} More recently, the condition has been described as an idiopathic environmental intolerance.^{1 9-11}

To date, tens of thousands of publications have addressed MCS in the international lay and scientific literature.¹² However, little consensus exists regarding MCS, including defining characteristics and the underlying nature of the condition as toxigenic or psychogenic.¹³⁻¹⁵ Prevalence estimates vary considerably, suggesting differences in operationalizations of the definition and diagnostic criteria for MCS.¹⁶⁻¹⁹ Individual symptoms reported by patients are not unique to MCS and the lack of consensus, including whether MCS should be considered a distinct disorder, hinders the identification and differential diagnosis of MCS in clinical practice.²⁰⁻²² A large number of potentially underlying mechanisms of action for MCS have been described that span immune system dysregulation, neural sensitization and hyperresponsivity, neurogenic inflammation, limbic system dysfunction, oxidative stress hypothesis, genetic theories, and classical conditioning [4]. Regardless of the challenges in operationalizing definitions and establishing its etiology, MCS is an international phenomenon that has been

1
2
3 described in different formats and terms for decades [4]. It is a distressing and puzzling condition
4
5 for patients as well as their healthcare providers.²³⁻²⁵ Some mechanism of action considerations
6
7 have resulted in interventions for patients; however, no comprehensive review of the evaluated
8
9 treatment and management options exists that currently successfully supports patients describing
10
11 MCS symptoms.^{26,27} Surveys describe multiple, often not evidence-based treatment approaches
12
13 tried by patients, and the lack of clinical guidance leaves healthcare practitioners guessing how
14
15 to best address MCS in their patients.^{8,27-29}
16
17
18

19 Despite the large number of publications addressing MCS, there is a lack of research
20
21 syntheses providing an overview of the existing evidence base on MCS. However, we believe
22
23 that the existing evidence base needs to be mapped as a first step in order to advance research
24
25 and practice in this complex field. Before trying to establish the most salient definition of MCS
26
27 or most plausible mechanism of action leading to MCS in a systematic review, a scoping review
28
29 should systematically identify, explore, and characterize the existing research literature. The
30
31 proposed work will be based on a scoping review of the literature. Scoping reviews are
32
33 systematic literature review approaches that explore research fields to systematically capture the
34
35 volume and content of scientific literature that is relevant to guiding questions for the review.³⁰⁻³²
36
37 To address the complexity of the topic, it is critical that a comprehensive review casts a wide net,
38
39 incorporating research from different disciplines and conceptual positions. Our planned scoping
40
41 review will use extensive literature searches to map the existing literature. The review will
42
43 provide an overview of definitions and diagnostic criteria of MCS, identify prevalence and
44
45 incidence research, document the body of evidence addressing the question of whether MCS is a
46
47 distinct disorder, compile a compendium of suggested mechanisms of MCS, and provide an
48
49 overview of the literature on MCS treatment and management that has been published to date.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 This scoping review was prospectively registered and will be conducted according to
4 established procedures to provide a systematic and transparent exploration of the literature.³³ The
5 findings of the scoping review will be presented as an evidence map. Evidence maps are an
6 evidence synthesis tool that provide a visualization of a large evidence base to provide readers
7 with a concise overview.^{34 35} Evidence maps allow a visual and user friendly research overview
8 suitable for a large and diverse research field, effectively mapping the existing evidence.^{34 36-43}
9 The evidence map will document the presence and absence of research on MCS for the five
10 questions guiding the review in a user-friendly format.
11
12
13
14
15
16
17
18
19
20
21

22 Guiding Questions

23
24
25 The following review questions will guide the scoping review:

- 26 • GQ1: How is Multiple Chemical Sensitivity (MCS) defined and how is it diagnosed?
- 27 • GQ2: What methods are used to report prevalence and incidence estimates of MCS?
- 28 • GQ3: What are the characteristics of the body of scientific evidence that addresses
29 whether MCS is a distinct disorder or syndrome?
- 30 • GQ4: What underlying mechanisms for MCS have been proposed in the scientific
31 literature?
- 32 • GQ5: Which treatment and management approaches for MCS have been evaluated in
33 empirical research studies?

34 Review Aim

35
36
37 The review will answer the guiding questions with the identified scientific literature in a user-
38 friendly format. A systematic evidence map will provide a visualization of the existing evidence
39 and research gaps.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods and Analysis

The review is registered in the Open Science Framework (OSF).¹² The scoping review will follow the steps for scoping reviews outlined by Arksey and Malloy: Stage 1: identifying the research question; Stage 2: identifying relevant studies; Stage 3: study selection; Stage 4: charting the data; Stage 5: collating, summarizing and reporting the results. In addition, a consultation exercise to inform and validate findings from the scoping review will be conducted. The following outlines the steps in detail. The reporting will follow established guidelines.^{31 44}

Search Strategy

We will search the international literature on MCS using different taxonomy and nomenclature. Literature searches will be designed, executed, and documented by an experienced evidence review center librarian. The scoping review addresses multiple aspects of MCS and the search strategy covers multiple databases to ensure that all scientific literature relevant to MCS will be identified. The use of multiple sources is a key method to minimize selection bias being introduced into the review. We plan on searching the following databases to obtain a diverse set of citations potentially relevant to MCS from different disciplines:

- PubMed (biomedical)
- CINAHL (nursing)
- Embase (biomedical)
- Web of Science (general scientific database)
- Scopus (health sciences)

- 1
- 2
- 3 • PsycINFO (behavioral and social sciences)
- 4
- 5
- 6 • Healthcare Administration Database (public health administration)
- 7
- 8 • Current Contents Connect (multidisciplinary)
- 9
- 10
- 11 • BIOSIS Citation Index (life sciences)
- 12
- 13 • Environment Index (environmental research)
- 14
- 15 • Environmental Science Database
- 16
- 17 • HERO (Health & Environmental Research Online)
- 18
- 19
- 20 • SciFinder (chemical literature)
- 21
- 22 • Agricultural & Environmental Science Collection (includes AGRICOLA, environmental
- 23 research)
- 24
- 25

26
27 The search strategy is shown in the appendix. Content experts provided input regarding
28 individual search terms and databases.
29

30
31 In addition, our review will be informed by existing comprehensive reviews on the topic.^{4 45}
32
33 Reviews will be systematically identified through the systematic review filter in PubMed and the
34
35 Cochrane Database of Systematic Review (SDSR). We will screen the international registry
36
37 PROSPERO for ongoing efforts that could inform this project during the update search period;
38
39 currently, the registry includes only two ongoing efforts that address selected aspects of MCS.⁴⁶
40
41

42
43 47

44
45 For individual guiding questions, we will search additional sources, including selected and
46
47 pre-specified grey literature sources. For definitions and diagnostic criteria (GQ1), we will
48
49 search the website of global organizations such as the World Health Organization (WHO).
50
51 Searches for prevalence research (GQ2) will reference-mine existing reviews.⁵ We will review
52
53 reports identified in PubMed Health regarding consensus statements on MCS as a distinct
54
55

1
2
3 disorder (GQ3) and regarding published suggested mechanisms of action (GQ4). For
4
5 intervention studies (GQ5), we will search repositories of practice guidelines including [G-I-N](#)⁴⁸
6
7 and the [ECRI](#)-maintained guideline database.⁴⁹ In addition, we will search the U.S. trial registry
8
9 [clinicaltrials.gov](#)⁵⁰ and the International Clinical Trials Registry Platform maintained by the
10
11 [WHO](#).⁵¹
12
13

14 In addition, we will reference-mine relevant reviews and included studies and consult with
15
16 content experts to ensure that all relevant literature has been captured.
17
18

19 20 Eligibility Criteria and Screening 21

22
23 We will use a PICOTSO (population, intervention/exposure, comparator, outcome, timing,
24
25 setting, and other limiter) framework to structure the eligibility criteria. For each guiding
26
27 question, we will determine detailed inclusion and exclusion criteria. The criteria, thus far, are as
28
29 follows:
30
31

- 32
33 • Population:
 - 34
35 ○ Publications reporting definitions (GQ1) and studies reporting on the prevalence
36
37 and incidence (GQ2) of MCS will be limited to those that explicitly state *multiple*
38
39 *chemical sensitivity, chemical intolerance, or idiopathic environmental*
40
41 *intolerance* with a reference to chemical sensitivities. Publications reporting
42
43 exclusively on the prevalence of individual sick building syndrome symptoms
44
45 will be excluded.
46
47
 - 48
49 ○ Eligible populations for GQ3 and GQ4 will include those that either state *multiple*
50
51 *chemical sensitivity* or those that are characterized by symptoms of idiopathic
52
53 environmental intolerance with a reference to chemical sensitivity. Populations
54
55 will not be restricted to human participants diagnosed with MCS, and will instead
56
57
58
59

1
2
3 include a wide range of research that may contribute to establishing MCS as a
4 diagnosis and exploring relevant mechanisms.
5
6

- 7
8 ○ GQ5 will be limited to samples of human participants where a majority (75% or
9 more) is diagnosed with MCS, idiopathic environmental intolerance for
10 chemicals, the equivalent of the ICD-10-CM Code F45.9 (somatoform disorder,
11 unspecified), or studies that report on a subgroup of the patients of interest.
12
13
14
15
16
17 ● Intervention/exposure/independent variable:
18
19 ○ We will accept definitions of MCS and descriptions that include diagnostic
20 criteria (GQ1).
21
22 ○ Prevalence and incidence measures need to state the criteria of MCS clearly to be
23 eligible (GQ2).
24
25 ○ GQ3 studies assessing whether MCS is a distinct disorder (i.e., distinct from other
26 “physical” disorders or “psychiatric” disorders) need to provide empirical
27 evidence of discriminatory power to support the authors’ conclusions or need to
28 be based on formal expert consensus methods. Opinions of individual authors will
29 not be eligible.
30
31 ○ Eligible publications suggesting underlying mechanisms (GQ4) may include
32 evidence for the onset of MCS or the course of the disease, including TILT
33 (toxicant-induced loss of tolerance describing an initiation and a triggering stage).
34
35 ○ Studies evaluating interventions (GQ5) to prevent, manage, or treat MCS will be
36 eligible. Interventions will not be restricted by the content or treatment approach,
37 and may include interventions aiming to avoid triggers, focusing on coping with
38 MCS symptoms, desensitization, or addressing the causes of MCS. In addition,
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 interventions in patients diagnosed with MCS will be eligible regardless of the
4 intervention focus (patient-centered rather than intervention-centered approach).

5
6 Case studies of individual patients will be included if focused on intervention
7 rather than the natural course of the condition and the description is published in a
8 peer-reviewed scientific journal.
9

- 10
11
12
13
14 • Comparator: Studies will be eligible regardless of the presence of a comparator.
- 15
16
17 • Outcome: GQ1 publications will need to provide sufficiently detailed descriptions that
18 can be operationalized as a definition or diagnostic criteria. GQ2 studies will need to
19 report a numerical estimate of the prevalence or incidence of MCS. GQ3 and GQ4 will
20 not be limited by reported outcomes. GQ5 studies may report on patient health (self or
21 clinician report), physiological or psychosocial measures assessing the effect of the
22 intervention (effectiveness as well as safety indicators); quantitative and qualitative data
23 will be eligible. Studies reporting only on treatment uptake, patient or provider
24 acceptability of treatments, or treatment costs will be excluded.
- 25
26
27 • Timing: GQ1 studies will be included regardless of the publication year (e.g., definitions
28 from the 1980s are eligible). GQ2 studies will be eligible regardless of the timing of the
29 exposure or assessment (e.g., childhood exposure, symptoms tested in adults); however,
30 only prevalence and incidence estimate elicited in the last ten years will be eligible
31 (historic estimates will be excluded). GQ3 and GQ4 studies will not be restricted by time
32 of exposure or follow-up, and retrospective, concurrent, and prospective studies will be
33 eligible. GQ5 studies will be included regardless of the intervention duration and follow
34 up.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Setting: Studies will not be restricted by setting and will be drawn from the international literature.
- Other limiters: English-language publications disseminated to a wide audience through a scientific journal will be eligible. Studies published in abbreviated form (e.g., conference abstracts) will not be eligible for inclusion.

Systematic reviews and relevant narrative reviews will be retained for reference-mining.

Multiple publications on the same study (i.e., studies defined by the included participants) will be consolidated into one study record to ensure that a given study is not counted multiple times regardless of the number of publications reported on the study. The literature flow will be transparently documented in a citation management program.

Inclusion Screening Process

We will use an online database (DistillerSR) designed for literature reviews to screen the search output. The team will design detailed citation and full text screening forms to ensure a transparent, consistent, and unambiguous approach. Citations found to be potentially relevant by at least one reviewer will be obtained as full text. Citations screening will be supported by machine learning algorithms to reduce reviewer errors and bias. All citations excluded by a human reviewer will be screened for relevance by the machine learning algorithm to ensure that no potentially relevant study has been missed.

Full text screening will apply the detailed eligibility criteria. Training will ensure a shared understanding of all inclusion and exclusion criteria across reviewers. Full text publications will be screened by two independent reviewers and any discrepancies will be resolved through discussion in the review team. Dual screening reduces reviewer bias and errors and is critical for this complex topic. The screening decisions and reasons for exclusion of studies will be tracked

1
2
3 in the online database and citation management software. This allows us to reconstruct a detailed
4 literature flow and facilitates the documentation of included and excluded publications. Reasons
5 for exclusion will match the exclusion criteria dimensions to orient the reader. The literature
6 flow will be documented in a flow diagram.
7
8
9
10

11
12 Studies excluded at full text will be documented in the appendix of the review together
13 with a reason for exclusion. We will retain background papers, i.e., papers to cite or reviews to
14 reference-mine. We will report the number of included studies and the number of publications
15 reporting on each study across the review and for each guiding question.
16
17
18
19
20

21 22 Data Abstraction

23
24
25 The data abstraction will provide a concise overview of the evidence.
26

27
28 For **GQ1** (definitions and diagnostic criteria), we will document the suggested definitions
29 and the approach to establish it. We will document published diagnostic criteria of MCS and for
30 diagnostic accuracy studies, the type (e.g., self report questionnaire, objective test such as
31 exposure chamber and challenge test) and name of the test will be recorded.
32
33
34
35
36

37 For **GQ2** (prevalence and incidence), we will document the data type (e.g., prevalence or
38 incidence), the method of assessment (e.g., self report, medical record), and the operationalization
39 of MCS (definition, criteria). We will distinguish general, unselected populations (e.g., students)
40 from targeted samples with potentially increased risk (e.g., Gulf War veterans). For each study, we
41 will record the country, sample size, and year of estimate, and identify any published prospective
42 studies.
43
44
45
46
47
48
49

50
51 For **GQ3** (MCS as a distinct disorder), we will document the aim of the study, the employed
52 study design, and the analytic approach to evaluate MCS as a distinct disorder. We will record the
53 type of research approach used to determine whether MCS should or should not be considered a
54
55
56
57
58
59

1
2
3 distinct disorder or syndrome (e.g., establishing a unique biomarker, analyzing symptom clusters,
4 documenting explained variance)²² and differentiate the use of direct, mechanistic, and parallel
5 evidence by the authors.⁵²⁻⁵⁴ We will abstract the authors' conclusion regarding their conceptual
6 agreement with MCS as a distinct disorder with a differential clinical diagnosis.
7
8
9
10

11
12 For **GQ4** (underlying mechanisms), we will broadly categorize the study type and approach
13 to indicate whether the study addresses the etiology or pathogenic development and whether the
14 approach assumes a biological or psychological hypothesis. For each study, we will categorize the
15 suggested mechanisms (e.g., immune system dysregulation, neural sensitization and
16 hyperresponsivity, neurogenic inflammation, limbic system dysfunction, oxidative stress
17 hypothesis, genetic theories, or classical conditioning).⁵ This will involve collating and reviewing
18 all identified mechanisms and establishing a categorization system based on the published literature
19 and identified approaches. We will also establish a compendium of frameworks and diagrams
20 reported by the authors. For this, figures published under the Creative Commons will be included in
21 the compendium; for all others, the publisher will be contacted to request permission to use the
22 figure.
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 For **GQ5** (therapy and management for MCS) will collate all identified interventions and
38 broadly categorizing interventions as prevention, management, or treatment. We will document the
39 focus of the intervention (e.g., aiming to alter the course of the condition, coping strategies) together
40 with the broad therapeutic approach (removing triggers from environment, diet, supplements,
41 masks, devices, [off-label] medication, psychological approaches). The categorization system will
42 built on existing reviews and the identified empirical research.²² We will also abstract the author
43 group, publication year, and country.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Data will be abstracted by one reviewer and checked by an experienced literature review
4 methodologist. We will export data into tables and figures or data files for further analysis.
5
6
7

8 Consultation Exercise 9

10
11 The last step of the scoping review process will be a consultation exercise. We will ask multi-
12 disciplinary technical experts and stakeholders in MCS research, practice, and advocacy to
13 review the results of the scoping review. These reviewers will not have been involved in the
14 review process and will assess the review *de novo*. Previous experiences have shown that this
15 last step of stakeholder involvement provides invaluable input and adds to the usefulness and
16 validity of the end product.^{33 55 56} The consultation exercise will be conducted as an online survey
17 sent to participants together with the review to elicit structured feedback on the content and
18 presentation of the review. The input will contribute to the presentation of the scoping review
19 results.
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Patient and Public Involvement 34

35
36 The planned review was presented at a stakeholder meeting organized by the funding agency that
37 included a patient representative. Several stakeholders are also part of the scientific steering
38 committee that reviewed this protocol (see acknowledgement section). The results of the review
39 will be distributed to stakeholders in a formal consultation exercise as outlined above. This step
40 will be instrumental in ensuring a user-friendly presentation of results that is useful to patients
41 and the public.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Result Presentation

Characteristics of all studies meeting inclusion criteria will be documented in concise evidence tables to provide a broad documentation of the underlying evidence base. Findings across studies will be documented in an evidence map. This visual and user friendly research overview will map the existing evidence on MCS.

The evidence map will use a bubble plot format with a limited number of dimensions to display the existing research. Each bubble in the plot will represent a study and the size of the bubble will represent the size of the study. The plot will use the x-axis to display existing types of research studies to characterize the evidence base further. The y-axis can be used to characterize the guiding question addressed by the research. In addition, the shape of the bubble and/or shading may represent different study designs and methodological characteristics. The optimal display will be selected based on input from the consultation exercise.

The tables and figures will be accompanied by a narrative that summarizes the identified evidence base. This scoping review and evidence map will provide a broad overview of the existing research on MCS. It also aims to facilitate a future systematic review of the literature that will answer definitive research questions (e.g., what is the prevalence of MCS and the effectiveness of treatments for MCS). Scoping and mapping has become increasingly useful to prepare more definitive systematic reviews that answer closed questions, in particular for large and controversial topics.^{34 35 40 44 57 58} The scoping review will provide context and information on which topic areas are to date amenable to a formal systematic review of the literature. The future systematic review will address a narrower scope of approaches that have been identified in this

1
2
3 scoping review, assess the quality of evidence for distinct topics of interest, and synthesize the
4
5 evidence.
6

7
8 In addition to documenting the existing evidence base, we will clearly outline gaps in the
9
10 literature identified in this scoping review. The gap presentation will use the scoping review's
11
12 eligibility framework to transparently document existing gaps and future research needs. The gap
13
14 analysis will make concrete recommendations to facilitate future research.
15
16

17 18 19 20 21 Ethics and Dissemination and Data Availability 22

23
24
25 The scoping review was determined to be exempt from further review by the University of
26
27 Southern California Institutional Review Board (IRB) review in July 2022 (ID UP-22-00516).
28

29 The results of the review will be disseminated through a journal manuscript. Data of the scoping
30
31 review will be publicly available through an online data repository (SRDR+).
32
33

34 35 36 Author Contributions 37

38
39 SH obtained funding; SH, MD, KR, OA, JJ designed the study, SH, MD, MB, JR, AIM, CP
40
41 screened literature to prepare this manuscript; AnM and DT manage the data; SY conducted the
42
43 literature searches; all authors contributed conceptually to the work and edited this manuscript.
44
45
46

47 48 49 Competing Interests 50

51
52 None of the authors have any conflicts of interest to declare.
53
54
55
56
57
58
59
60

Funding

This work was supported by the Marilyn Brachman Hoffman Foundation [ID 015153-00001].

Acknowledgements

We thank Dori Germolec, Howard Hu, Jon Samet, and Roberta White for their thoughtful comments. We also thank Tatjana Walker for her feedback and support.

References

1. Consensus on Multiple Chemical Sensitivity. Multiple chemical sensitivity: a 1999 consensus. Arch Environ Health 1999;**54**(3):147-9 doi: 10.1080/00039899909602251[published Online First: Epub Date]].
2. Workshop on Multiple Chemical S, World Health Organization. Programme for the Promotion of Chemical S, International Programme for Chemical S. Report of the Workshop on Multiple Chemical Sensitivities (MCS), Berlin, Germany, 21-23 February 1996. Geneva: World Health Organization, 1996.
3. Cone JE, Harrison R, Reiter R. Patients with multiple chemical sensitivities: clinical diagnostic subsets among an occupational health clinic population. Occup Med 1987;**2**(4):721-38
4. Driesen L, Patton R, John M. The impact of multiple chemical sensitivity on people's social and occupational functioning; a systematic review of qualitative research studies. J

- 1
2
3 Psychosom Res 2020;**132**:109964 doi: 10.1016/j.jpsychores.2020.109964[published
4
5 Online First: Epub Date]].
6
7
8 5. Zucco GM, Doty RL. Multiple Chemical Sensitivity. Brain Sci 2021;**12**(1) doi:
9
10 10.3390/brainsci12010046[published Online First: Epub Date]].
11
12 6. Winder C. Mechanisms of multiple chemical sensitivity. Toxicol Lett 2002;**128**(1-3):85-97
13
14 doi: 10.1016/s0378-4274(01)00536-7[published Online First: Epub Date]].
15
16
17 7. Cullen MR. The worker with multiple chemical sensitivities - An overview. Occup. Med.-State
18
19 Art Rev. 1987;**2**(4):655-61
20
21 8. Alameda Cuesta A, Pazos Garcíandía Á, Oter Quintana C, Losa Iglesias ME. Fibromyalgia,
22
23 Chronic Fatigue Syndrome, and Multiple Chemical Sensitivity: Illness Experiences. Clin
24
25 Nurs Res 2021;**30**(1):32-41 doi: 10.1177/1054773819838679[published Online First:
26
27 Epub Date]].
28
29
30 9. AAAI Board of Directors. Idiopathic environmental intolerances. American Academy of
31
32 Allergy, Asthma and Immunology (AAAAI) Board of Directors. J Allergy Clin Immunol
33
34 1999;**103**(1 Pt 1):36-40
35
36
37 10. ACOEM Environmental Medicine Committee. ACOEM position statement. Multiple
38
39 chemical sensitivities: idiopathic environmental intolerance. College of Occupational and
40
41 Environmental Medicine. J Occup Environ Med 1999;**41**(11):940-2
42
43
44 11. Lacour M, Zunder T, Schmidtke K, Vaith P, Scheidt C. Multiple chemical sensitivity
45
46 syndrome (MCS)--suggestions for an extension of the U.S. MCS-case definition. Int J
47
48 Hyg Environ Health 2005;**208**(3):141-51 doi: 10.1016/j.ijheh.2005.01.017[published
49
50 Online First: Epub Date]].
51
52
53
54
55
56
57
58
59
60

- 1
2
3 12. Hempel S, Danz M, Robinson KA, Bolshakova M, Imasuen E, Rodriguez J, et al. Multiple
4
5 Chemical Sensitivity. Secondary Multiple Chemical Sensitivity 2022. osf.io/4a3wu
6
7
8 13. Regal Ramos RJ. [Can we rule out that fibromyalgia, chronic fatigue syndrome and multiple
9
10 chemical sensitivity are psychosomatic diseases?]. *Semergen* 2015;**41**(7):349-53 doi:
11
12 10.1016/j.semerg.2015.04.015[published Online First: Epub Date]].
13
14
15 14. Staudenmayer H. Clinical consequences of the EI/MCS "diagnosis": two paths. *Regul*
16
17 *Toxicol Pharmacol* 1996;**24**(1 Pt 2):S96-110 doi: 10.1006/rtp.1996.0084[published
18
19 Online First: Epub Date]].
20
21
22 15. Gots RE. Multiple chemical sensitivities: distinguishing between psychogenic and
23
24 toxicodynamic. *Regul Toxicol Pharmacol* 1996;**24**(1 Pt 2):S8-15 doi:
25
26 10.1006/rtp.1996.0071[published Online First: Epub Date]].
27
28
29 16. Heo Y, Kim SH, Lee SK, Kim HA. Factors Contributing to the Self-Reported Prevalence of
30
31 Multiple Chemical Sensitivity in Public Facility Workers and the General Population of
32
33 Korea. *J uoeh* 2017;**39**(4):249-58 doi: 10.7888/juoeh.39.249[published Online First:
34
35 Epub Date]].
36
37
38 17. Cui X, Lu X, Hiura M, Oda M, Hisada A, Miyazaki W, et al. Prevalence and interannual
39
40 changes in multiple chemical sensitivity in Japanese workers. *Environ Health Prev Med*
41
42 2014;**19**(3):215-9 doi: 10.1007/s12199-014-0378-6[published Online First: Epub Date]].
43
44
45 18. Kipen HM, Hallman W, Kelly-McNeil K, Fiedler N. Measuring chemical sensitivity
46
47 prevalence: a questionnaire for population studies. *Am J Public Health* 1995;**85**(4):574-7
48
49 doi: 10.2105/ajph.85.4.574[published Online First: Epub Date]].
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Dupas D, Dagher MA. [Multiple chemical sensitivity: a diagnosis not to be missed]. *Rev Mal Respir* 2013;**30**(2):99-104 doi: 10.1016/j.rmr.2012.06.016[published Online First: Epub Date]].
20. Dantoft TM, Andersson L, Nordin S, Skovbjerg S. Chemical intolerance. *Curr Rheumatol Rev* 2015;**11**(2):167-84 doi: 10.2174/157339711102150702111101[published Online First: Epub Date]].
21. Herr C, Eikmann T. [Environmental-medical diagnosis and therapy. Hasty diagnosis of unspecified environmental syndromes should be avoided]. *Fortschr Med* 1998;**116**(33):26-9
22. Watanabe M, Tonori H, Aizawa Y. Multiple chemical sensitivity and idiopathic environmental intolerance (part two). *Environ Health Prev Med* 2003;**7**(6):273-82 doi: 10.1007/bf02908886[published Online First: Epub Date]].
23. Sparks PJ, Daniell W, Black DW, Kipen HM, Altman LC, Simon GE, et al. Multiple chemical sensitivity syndrome: a clinical perspective. II. Evaluation, diagnostic testing, treatment, and social considerations. *J Occup Med* 1994;**36**(7):731-7
24. Gibson PR, Lindberg A. Physicians' perceptions and practices regarding patient reports of multiple chemical sensitivity. *ISRN Nurs* 2011;**2011**:838930 doi: 10.5402/2011/838930[published Online First: Epub Date]].
25. Phillips T, Rees T. (In)Visibility Online: The Benefits of Online Patient Forums for People with a Hidden Illness: The Case of Multiple Chemical Sensitivity (MCS). *Med Anthropol Q* 2018;**32**(2):214-32 doi: 10.1111/maq.12397[published Online First: Epub Date]].
26. Ross GH. Treatment options in multiple chemical sensitivity. *Toxicol Ind Health* 1992;**8**(4):87-94

- 1
2
3 27. Gibson PR, Elms AN, Ruding LA. Perceived treatment efficacy for conventional and
4
5 alternative therapies reported by persons with multiple chemical sensitivity. *Environ*
6
7 *Health Perspect* 2003;**111**(12):1498-504 doi: 10.1289/ehp.5936[published Online First:
8
9 Epub Date]].
- 10
11
12 28. Skovbjerg S, Johansen JD, Rasmussen A, Thorsen H, Elberling J. General practitioners'
13
14 experiences with provision of healthcare to patients with self-reported multiple chemical
15
16 sensitivity. *Scand J Prim Health Care* 2009;**27**(3):148-52 doi:
17
18 10.1080/02813430902888355[published Online First: Epub Date]].
- 19
20
21 29. Rest KM. A survey of AOEC physician practices and attitudes regarding multiple chemical
22
23 sensitivity. *Toxicol Ind Health* 1992;**8**(4):51-65
- 24
25
26 30. McGowan J, Straus S, Moher D, Langlois EV, O'Brien KK, Horsley T, et al. Reporting
27
28 scoping reviews-PRISMA ScR extension. *J Clin Epidemiol* 2020;**123**:177-79 doi:
29
30 10.1016/j.jclinepi.2020.03.016[published Online First: Epub Date]].
- 31
32
33 31. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension
34
35 for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*
36
37 2018;**169**(7):467-73 doi: 10.7326/M18-0850[published Online First: Epub Date]].
- 38
39
40 32. Peters MDJ, Marnie C, Colquhoun H, Garritty CM, Hempel S, Horsley T, et al. Scoping
41
42 reviews: reinforcing and advancing the methodology and application. *Syst Rev*
43
44 2021;**10**(1):263 doi: 10.1186/s13643-021-01821-3[published Online First: Epub Date]].
- 45
46
47 33. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International*
48
49 *Journal of Social Research Methodology* 2005;**8**(1):19-32
- 50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 34. Miake-Lye IM, Hempel S, Shanman R, Shekelle PG. What is an evidence map? A systematic
4 review of published evidence maps and their definitions, methods, and products. *Syst*
5
6
7
8 *Rev* 2016;**5**:28 doi: 10.1186/s13643-016-0204-x[published Online First: Epub Date]].
9
- 10 35. Hempel S. *Conducting Your Literature Review*. Washington, DC: American Psychological
11
12 Association, 2019.
13
- 14 36. Apaydin EA, Maher AR, Raaen L, Motala A, Baxi S, Shanman RM, et al. The Use of
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
37. Apaydin EA, Partikian A, Rollison J, Baxi S, Fu N, Hempel S. An evidence map of
treatments for infantile epilepsy. *Epilepsy Res* 2021;**178**:106781 doi:
10.1016/j.epilepsyres.2021.106781[published Online First: Epub Date]].
38. Apaydin EA, Richardson AS, Baxi S, Vockley J, Akinniranye O, Ross R, et al. An evidence
map of randomised controlled trials evaluating genetic therapies. *BMJ Evid Based Med*
2020 doi: 10.1136/bmjebm-2020-111448[published Online First: Epub Date]].
39. Bouskill K, Hempel S, Richardson A, Ganz PA, Baxi S, Zutshi R, et al. Evidence map of
ductal carcinoma in situ management options. *Menopause* 2019;**26**(11):1250-58 doi:
10.1097/GME.0000000000001397[published Online First: Epub Date]].
40. Hempel S, Taylor SL, Solloway MR, Miake-Lye IM, Beroes JM, Shanman R, et al. Evidence
Map of Acupuncture. Washington (DC), 2014.
41. Hilton LG, Marshall NJ, Motala A, Taylor SL, Miake-Lye IM, Baxi S, et al. Mindfulness
meditation for workplace wellness: An evidence map. *Work* 2019;**63**(2):205-18 doi:
10.3233/WOR-192922[published Online First: Epub Date]].

- 1
2
3 42. Maher AR, Apaydin EA, Raaen L, Motala A, Baxi S, Hempel S. The Use of Technology in
4
5 the Clinical Care of Anxiety: An Evidence Map. *Psychiatr Serv* 2021;**72**(2):195-99 doi:
6
7 10.1176/appi.ps.202000178[published Online First: Epub Date]].
8
9
10 43. Solloway MR, Taylor SL, Shekelle PG, Miake-Lye IM, Beroes JM, Shanman RM, et al. An
11
12 evidence map of the effect of Tai Chi on health outcomes. *Syst Rev* 2016;**5**(1):126 doi:
13
14 10.1186/s13643-016-0300-y[published Online First: Epub Date]].
15
16
17 44. Haddaway N, Macura B, Whaley P, Pullin A. ROSES for Systematic Review Protocols.
18
19 Version 1.0: figshare, 2018. 10.6084/m9.figshare.5897269.v4.
20
21 [https://figshare.com/articles/online_resource/ROSES_for_Systematic_Review_Protocols/
22
23 5897269](https://figshare.com/articles/online_resource/ROSES_for_Systematic_Review_Protocols/5897269)
24
25
26 45. De Luca C, Raskovic D, Pacifico V, Thai JC, Korkina L. The search for reliable biomarkers
27
28 of disease in multiple chemical sensitivity and other environmental intolerances. *Int J*
29
30 *Environ Res Public Health* 2011;**8**(7):2770-97 doi: 10.3390/ijerph8072770[published
31
32 Online First: Epub Date]].
33
34
35 46. Mette Toft, Rukayya Nasir Sani, Danijela Gasevic, Ruth McQuillan, Anne Martin. Multiple
36
37 chemical sensitivity: prevalence, triggers, symptoms, and impact on lifestyle. A
38
39 systematic review of epidemiological studies. 2018
40
41
42 47. Sunita Vohra, Mohammad Karkhaneh, Salima Punja, Susanne King-Jones, Karin Olson.
43
44 Systematic review of evidence for the effectiveness of mind-body interventions to treat
45
46 Multiple Chemical Sensitivity (MCS). 2017
47
48
49 48. Guidelines International Network. Welcome to Guidelines International Network. Secondary
50
51 Welcome to Guidelines International Network. <https://g-i-n.net/>.
52
53
54
55
56
57
58
59
60

- 1
2
3 49. ECRI. ECRI Guidelines Trust. Secondary ECRI Guidelines Trust.
4
5 <https://www.ecri.org/solutions/ecri-guidelines-trust>.
6
7
8 50. U.S. National Library of Medicine. ClinicalTrials Homepage. Secondary ClinicalTrials
9
10 Homepage. <https://clinicaltrials.gov/>.
11
12 51. World Health Organization. International Clinical Trials Registry Platform. Secondary
13
14 International Clinical Trials Registry Platform. <https://trialsearch.who.int/>.
15
16
17 52. Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st
18
19 century: how data integration has changed causal inference in molecular epidemiology.
20
21 Emerg Themes Epidemiol 2015;**12**:14 doi: 10.1186/s12982-015-0037-4[published Online
22
23 First: Epub Date]].
24
25
26 53. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med
27
28 1965;**58**:295-300
29
30
31 54. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can
32
33 Bradford Hill's 'guidelines for causation' contribute? J R Soc Med 2009;**102**(5):186-94
34
35 doi: 10.1258/jrsm.2009.090020[published Online First: Epub Date]].
36
37
38 55. Hempel S, Bolshakova M, Turner B, Dinalo J, Rose D, Motala A, et al. Evidence-Based
39
40 Quality Improvement: A Scoping Review of the Literature. Journal of General Internal
41
42 Medicine in press
43
44
45 56. Torriani-Pasin C, Demers M, Polese JC, Bishop L, Wade E, Hempel S, et al. mHealth
46
47 technologies used to capture walking and arm use behavior in adult stroke survivors: a
48
49 scoping review beyond measurement properties. Disabil. Rehabil. 2021:1-13 doi:
50
51 10.1080/09638288.2021.1953623[published Online First: Epub Date]].
52
53
54
55
56
57
58
59
60

- 1
2
3 57. United States Environmental Protection Agency (EPA). ORD Staff Handbook for
4
5 Developing IRIS Assessments (Public Comment Draft, Nov. 2020). Secondary ORD
6
7 Staff Handbook for Developing IRIS Assessments (Public Comment Draft, Nov. 2020)
8
9
10 2020. https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=350086.
11
12 58. Hempel S, Xenakis L, Danz M. Systematic Reviews for Occupational Safety and Health
13
14 Questions: Resources for Evidence Synthesis: RAND Corporation, 2016:102.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix: Search Strategies

Multiple Chemical Sensitivity Scoping Review Protocol

PubMed

"multiple chemical sensitivity"[MeSH Terms] OR ("multiple"[Title/Abstract] AND "chemical"[Title/Abstract] AND "sensitivity"[Title/Abstract]) OR "multiple chemical sensitivity"[Title/Abstract] OR ("multiple"[Title/Abstract] AND "chemical"[Title/Abstract] AND "sensitivities"[Title/Abstract]) OR "multiple chemical sensitivities"[Title/Abstract] OR "MCS syndrome"[Title/Abstract] OR "chemical intolerance"[Title/Abstract] OR "chemically intolerant"[Title/Abstract] OR "chemical hypersensitivity"[Title/Abstract] OR "chemical AIDS"[Title/Abstract] OR "chemical sensitivity disorder"[Title/Abstract] OR "chemical sensitivity syndromes"[Title/Abstract] OR "chemophobia"[Title/Abstract] OR "environmental chemical odor intolerance"[Title/Abstract] OR "sensitivity to environmental chemicals"[Title/Abstract] OR ("chemical"[Title/Abstract] AND "environmental illness"[Title/Abstract]) OR "chemically induced environmental illnesses"[Title/Abstract] OR "total allergy syndrome"[Title/Abstract] OR "twentieth century disease"[Title/Abstract] OR "20th century disease"[Title/Abstract] OR "sick building syndrome"[Title/Abstract] OR "building-related illness"[Title/Abstract] OR "toxicant induced loss of tolerance"[Title/Abstract] OR "Toxicant-Induced Loss of Tolerance"[Title/Abstract] OR "mast cell activation syndrome"[Title/Abstract] OR "idiopathic environmental intolerance"[Title/Abstract] OR "idiopathic environmental intolerances"[Title/Abstract] OR "idiopathic environmental illness"[Title/Abstract]

Limit: English language

Agricultural & Environmental Science Collection

(noft("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome")
OR noft("chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
"chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
"chemophobia") OR noft("environmental chemical odor intolerance" OR "sensitivity to
environmental chemicals" OR ("chemical" AND "environmental illness") OR "chemically
induced environmental illnesses") OR noft("total allergy syndrome") OR noft("twentieth century
disease" OR "20th century disease" OR "sick building syndrome" OR "building-related illness")
OR noft("toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance") OR
noft("mast cell activation syndrome") OR noft("idiopathic environmental intolerance" OR
"idiopathic environmental intolerances" OR "idiopathic environmental illness"))
AND
(stype.exact("Scholarly Journals" OR "Other Sources" OR "Reports")
AND
la.exact("ENG"))

BIOSIS

"multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
(Topic) or "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity"
OR "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes"
OR "chemophobia" (Topic) or "environmental chemical odor intolerance" OR "sensitivity to
environmental chemicals" OR ("chemical" AND "environmental illness") OR "chemically

1
2
3 induced environmental illnesses" (Topic) or "total allergy syndrome" (Topic) or "twentieth
4 century disease" OR "20th century disease" OR "sick building syndrome" OR "building-related
5 illness" (Topic) or "toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of
6 Tolerance" (Topic) or "mast cell activation syndrome" (Topic) or "idiopathic environmental
7 intolerance" OR "idiopathic environmental intolerances" OR "idiopathic environmental illness"
8 (Topic)
9

10
11
12
13
14
15
16
17 AND Article (Document Types)

18
19 AND English (Languages)
20
21
22
23

24 **CINAHL**

25
26 TI ("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
27 OR "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
28 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
29 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
30 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
31 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
32 century disease" OR "sick building syndrome" OR "building-related illness" OR "toxicant
33 induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" OR "mast cell activation
34 syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
35 intolerances" OR "idiopathic environmental illness") OR SU ("multiple chemical sensitivity"
36 OR "multiple chemical sensitivities" OR "MCS syndrome" OR "chemical intolerance" OR
37 "chemically intolerant" OR "chemical hypersensitivity" OR "chemical AIDS" OR "chemical
38 sensitivity disorder" OR "chemical sensitivity syndromes" OR "chemophobia" OR
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 "environmental chemical odor intolerance" OR "sensitivity to environmental chemicals" OR
4 ("chemical" AND "environmental illness") OR "chemically induced environmental illnesses" OR
5
6 "total allergy syndrome" OR "twentieth century disease" OR "20th century disease" OR "sick
7
8 building syndrome" OR "building-related illness" OR "toxicant induced loss of tolerance" OR
9
10 "Toxicant-Induced Loss of Tolerance" OR "mast cell activation syndrome" OR "idiopathic
11
12 environmental intolerance" OR "idiopathic environmental intolerances" OR "idiopathic
13
14 environmental illness") OR AB ("multiple chemical sensitivity" OR "multiple chemical
15
16 sensitivities" OR "MCS syndrome" OR "chemical intolerance" OR "chemically intolerant" OR
17
18 "chemical hypersensitivity" OR "chemical AIDS" OR "chemical sensitivity disorder" OR
19
20 "chemical sensitivity syndromes" OR "chemophobia" OR "environmental chemical odor
21
22 intolerance" OR "sensitivity to environmental chemicals" OR ("chemical" AND "environmental
23
24 illness") OR "chemically induced environmental illnesses" OR "total allergy syndrome" OR
25
26 "twentieth century disease" OR "20th century disease" OR "sick building syndrome" OR
27
28 "building-related illness" OR "toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of
29
30 Tolerance" OR "mast cell activation syndrome" OR "idiopathic environmental intolerance" OR
31
32 "idiopathic environmental intolerances" OR "idiopathic environmental illness")

33
34
35
36
37
38
39
40 AND

41
42 English language
43
44
45
46

47 **Current Contents**

48
49 "multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome" OR
50
51 "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
52
53 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
54
55
56
57
58
59
60

1
2
3 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
4 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
5 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
6 century disease" OR "sick building syndrome" OR "building-related illness" OR "toxicant
7 induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" OR "mast cell activation
8 syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
9 intolerances" OR "idiopathic environmental illness" (Topic)
10
11 and
12 English (Language)
13
14 and
15
16 Article or Review Article or Correction (Document Types)
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **EMBASE**

31
32 ('multiple chemical sensitivity':ti,ab,kw OR 'multiple chemical sensitivities':ti,ab,kw OR 'mcs
33 syndrome':ti,ab,kw OR 'chemical intolerance':ti,ab,kw OR 'chemically intolerant':ti,ab,kw OR
34 'chemical hypersensitivity':ti,ab,kw OR 'chemical aids':ti,ab,kw OR 'chemical sensitivity
35 disorder':ti,ab,kw OR 'chemical sensitivity syndromes':ti,ab,kw OR 'chemophobia':ti,ab,kw OR
36 'environmental chemical odor intolerance':ti,ab,kw OR 'sensitivity to environmental
37 chemicals':ti,ab,kw OR ('chemical':ti,ab,kw AND 'environmental illness':ti,ab,kw) OR
38 'chemically induced environmental illnesses':ti,ab,kw OR 'total allergy syndrome':ti,ab,kw OR
39 'twentieth century disease':ti,ab,kw OR '20th century disease':ti,ab,kw OR 'sick building
40 syndrome':ti,ab,kw OR 'building-related illness':ti,ab,kw OR 'toxicant induced loss of
41 tolerance':ti,ab,kw OR 'toxicant-induced loss of tolerance':ti,ab,kw OR 'mast cell activation
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 syndrome':ti,ab,kw OR 'idiopathic environmental intolerance':ti,ab,kw OR 'idiopathic
4 environmental intolerances':ti,ab,kw OR 'idiopathic environmental illness':ti,ab,kw)

5
6
7
8 AND

9
10 english:la

11
12 AND

13
14 ('article'/it OR 'review'/it)

15
16
17
18
19 **Environment Index**

20
21 TI ("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
22 OR "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
23 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
24 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
25 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
26 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
27 century disease" OR "sick building syndrome" OR "building-related illness" OR "toxicant
28 induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" OR "mast cell activation
29 syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
30 intolerances" OR "idiopathic environmental illness") OR SU ("multiple chemical sensitivity"
31 OR "multiple chemical sensitivities" OR "MCS syndrome" OR "chemical intolerance" OR
32 "chemically intolerant" OR "chemical hypersensitivity" OR "chemical AIDS" OR "chemical
33 sensitivity disorder" OR "chemical sensitivity syndromes" OR "chemophobia" OR
34 "environmental chemical odor intolerance" OR "sensitivity to environmental chemicals" OR
35 ("chemical" AND "environmental illness") OR "chemically induced environmental illnesses" OR

1
2
3 "total allergy syndrome" OR "twentieth century disease" OR "20th century disease" OR "sick
4 building syndrome" OR "building-related illness" OR "toxicant induced loss of tolerance" OR
5
6 "Toxicant-Induced Loss of Tolerance" OR "mast cell activation syndrome" OR "idiopathic
7
8 environmental intolerance" OR "idiopathic environmental intolerances" OR "idiopathic
9
10 environmental illness") OR AB ("multiple chemical sensitivity" OR "multiple chemical
11
12 sensitivities" OR "MCS syndrome" OR "chemical intolerance" OR "chemically intolerant" OR
13
14 "chemical hypersensitivity" OR "chemical AIDS" OR "chemical sensitivity disorder" OR
15
16 "chemical sensitivity syndromes" OR "chemophobia" OR "environmental chemical odor
17
18 intolerance" OR "sensitivity to environmental chemicals" OR ("chemical" AND "environmental
19
20 illness") OR "chemically induced environmental illnesses" OR "total allergy syndrome" OR
21
22 "twentieth century disease" OR "20th century disease" OR "sick building syndrome" OR
23
24 "building-related illness" OR "toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of
25
26 Tolerance" OR "mast cell activation syndrome" OR "idiopathic environmental intolerance" OR
27
28 "idiopathic environmental intolerances" OR "idiopathic environmental illness")
29
30
31 AND
32
33 English language
34
35
36
37
38
39
40
41
42

43 Environmental Science

44 (not("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
45
46 OR "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
47
48 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
49
50 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
51
52 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
53
54
55
56
57
58
59
60

1
2
3 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
4 century disease" OR "sick building syndrome" OR "building-related illness" OR "toxicant
5 induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" OR "mast cell activation
6 syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
7 intolerances" OR "idiopathic environmental illness") AND stype.exact("Reports" OR "Working
8 Papers" OR "Scholarly Journals") AND la.exact("English")) AND stype.exact("Reports" OR
9 "Working Papers" OR "Scholarly Journals")

10
11
12
13
14
15
16
17
18
19 And

20 Source Type: Reports, Scholarly Journals, Working Papers

21
22
23 AND

24 Language: English
25
26
27
28
29
30

31 **Healthcare Administration**

32
33 noft("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
34 OR "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
35 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
36 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
37 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
38 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
39 century disease" OR "sick building syndrome" OR "building-related illness" OR "toxicant
40 induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" OR "mast cell activation
41 syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
42 intolerances" OR "idiopathic environmental illness")Limits applied
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 AND

4
5 Source type: Reports, Scholarly Journals

6
7
8 AND

9
10 Language: English

11
12
13
14 **HERO**

15
16 "multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome" OR
17
18 "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
19
20 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
21
22 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
23
24 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
25
26 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
27
28 century disease" OR "sick building syndrome" OR "building-related illness" OR "mast cell
29
30 activation syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
31
32 intolerances" OR "idiopathic environmental illness"

33
34
35 AND

36
37
38 Language: English

39
40
41
42
43
44 **PsycINFO**

45
46 (noft("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome")
47
48 OR noft("chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
49
50 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
51
52 "chemophobia")) OR noft("environmental chemical odor intolerance" OR "sensitivity to
53
54
55
56
57
58
59
60

1
2
3 environmental chemicals" OR ("chemical" AND "environmental illness") OR "chemically
4 induced environmental illnesses") OR noft("total allergy syndrome") OR noft("twentieth century
5 disease" OR "20th century disease" OR "sick building syndrome" OR "building-related illness")
6
7 OR noft("toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance") OR
8
9 noft("mast cell activation syndrome") OR noft("idiopathic environmental intolerance" OR
10
11 "idiopathic environmental intolerances" OR "idiopathic environmental illness"))
12
13
14
15
16
17 AND
18
19 (la.exact("ENG"))
20
21
22 AND
23
24 stype.exact("Scholarly Journals"))
25
26
27

28 **SciFinder**

29
30 "multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "chemical intolerance"
31
32 OR "chemically intolerant" OR "chemical hypersensitivity" OR "chemical AIDS" OR "chemical
33 sensitivity disorder" OR "chemical sensitivity syndromes" OR "chemophobia" OR
34
35 "environmental chemical odor intolerance" OR "sensitivity to environmental chemicals" OR
36
37 ("chemical" AND "environmental illness") OR "chemically induced environmental illnesses" OR
38
39 "total allergy syndrome" OR "twentieth century disease" OR "20th century disease" OR "sick
40
41 building syndrome" OR "building-related illness" OR "toxicant induced loss of tolerance" OR
42
43 "Toxicant-Induced Loss of Tolerance" OR "mast cell activation syndrome" OR "idiopathic
44
45 environmental intolerance" OR "idiopathic environmental intolerances" OR "idiopathic
46
47 environmental illness"
48
49
50
51
52
53
54 AND
55
56
57
58
59
60

1
2
3 English language
4

5 AND
6

7 Exclude: Patent, Book, Commentary, Conference, Dissertation, Editorial, Letter
8
9

10
11
12 **SCOPUS**
13

14 (TITLE-ABS-KEY ("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR
15 "MCS syndrome" OR "chemical intolerance" OR "chemically intolerant" OR "chemical
16 hypersensitivity" OR "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical
17 sensitivity syndromes" OR "chemophobia" OR "environmental chemical odor intolerance"
18 OR "sensitivity to environmental chemicals" OR ("chemical" AND "environmental illness")
19 OR "chemically induced environmental illnesses" OR "total allergy syndrome" OR "twentieth
20 century disease" OR "20th century disease" OR "sick building syndrome" OR "building-
21 related illness" OR "toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of
22 Tolerance" OR "mast cell activation syndrome" OR "idiopathic environmental intolerance"
23 OR "idiopathic environmental intolerances" OR "idiopathic environmental illness")
24
25

26 AND
27

28 (LIMIT-TO (DOCTYPE, "ar") OR LIMIT-TO (DOCTYPE, "re"))
29
30

31 AND
32

33 (LIMIT-TO (LANGUAGE, "English"))
34
35
36
37

38
39
40
41
42
43
44
45
46
47
48
49 **Web of Science**
50

51 "multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome" OR
52 "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
53
54
55
56
57
58
59

1
2
3 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
4
5 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
6
7 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
8
9 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
10
11 century disease" OR "sick building syndrome" OR "building-related illness" OR "toxicant
12
13 induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" OR "mast cell activation
14
15 syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
16
17 intolerances" OR "idiopathic environmental illness" (Topic)
18
19
20

21 AND

22 English (Language)

23
24 AND

25
26 Article or Review Article (Document Types)
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Multiple Chemical Sensitivity Scoping Review Protocol: Overview of Research and MCS Construct

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-072098.R1
Article Type:	Protocol
Date Submitted by the Author:	10-Aug-2023
Complete List of Authors:	Hempel, Susanne; University of Southern California Danz, Margie; University of Southern California Robinson, Karen; Johns Hopkins Medicine, Division of Health Sciences Informatics Bolshakova, Maria; University of Southern California, Preventive Medicine Rodriguez, Jesus; University of Southern California Mears, Alanna; University of Southern California Pham, Cindy; University of Southern California Yagyu, Sachi; University of Southern California, Preventive Medicine Motala, Aneesa; University of Southern California, Southern California Evidence Review Center Tolentino, Danica; University of Southern California Akbari, Omid; University of Southern California, Molecular Microbiology and Immunology Johnston, Jill; USC Keck School of Medicine
Primary Subject Heading:	Diagnostics
Secondary Subject Heading:	Epidemiology
Keywords:	INTERNAL MEDICINE, Systematic Review, GENERAL MEDICINE (see Internal Medicine)

SCHOLARONE™
Manuscripts

Multiple Chemical Sensitivity Scoping Review Protocol: Overview of Research and MCS Construct

Susanne Hempel,¹ Margie Danz,¹ Karen A. Robinson,² Maria Bolshakova,¹ Jesus Rodriguez,¹
Alanna Mears,¹ Cindy Pham,¹ Sachi Yagyu,¹ Aneesa Motala,¹ Danica Tolentino,¹ Omid Akbari,³
Jill Johnston⁴

¹ Southern California Evidence Review Center, University of Southern California, Los Angeles,
USA

² Evidence-based Practice Center, Johns Hopkins University, Baltimore, USA

³ Molecular Microbiology and Immunology, University of Southern California, Los Angeles,
USA

⁴ Population and Public Health Science, University of Southern California, Los Angeles, USA

Corresponding author

Dr. Susanne Hempel; Southern California Evidence Review Center, University of Southern
California, Keck School of Medicine, 1845 N Soto Street, Los Angeles, CA 90033; USA;

susanne.hempel@med.usc.edu

Word count: 3,511

ABSTRACT

Introduction: Multiple Chemical Sensitivity (MCS) has been characterized by reported adverse responses to environmental exposures of common chemical agents (e.g., perfumes, paint, cleaning products, and other inhaled or ingested agents) in low doses considered non-toxic for the general population. There is currently no consensus on whether MCS can be established as a distinct disorder.

Methods and analysis: The scoping review of the literature will be guided by five questions: How is MCS defined and which diagnostic criteria have been proposed? What methods are used to report prevalence and incidence estimates of MCS? What are the characteristics of the body of scientific evidence that addresses whether MCS is a distinct disorder or syndrome? What underlying mechanisms for MCS have been proposed in the scientific literature? Which treatment and management approaches for MCS have been evaluated in empirical research studies? We will conduct a comprehensive search in 14 research databases. Citation screening will be supported by machine learning algorithms. Two independent reviewers will assess eligibility of full text publications against prespecified criteria. Data abstraction will support concise evidence tables. A formal consultation exercise will elicit input from experts and stakeholders regarding the review results and presentation. The existing evidence about MCS will be documented in a user-friendly visualization in the format of an evidence map.

Ethics and dissemination: Determined to be exempt from review (UP-22-00516). Results will be disseminated through a journal manuscript and data will be publicly accessible through an online data repository.

Registration: The protocol is registered in Open Science Framework (osf.io/4a3wu).

1
2
3
4
5 (249 words)
6
7
8
9
10

11 Keywords

12
13
14
15 Multiple Chemical Sensitivity, Idiopathic Environmental Intolerance, Chemical Intolerance,
16 Scoping Review, Evidence Map
17
18
19
20
21
22
23

24 Strengths and Limitations

- 25
26
27
28 • This scoping review will cast a wide net capturing multiple important aspects of the
29 complex construct multiple chemical sensitivity (MCS).
30
31
- 32
33 • A formal consultation exercise will provide input from experts and stakeholders.
34
- 35
36 • The existing research on MCS will be documented in a user-friendly visualization in the
37 format of an evidence map.
38
39
- 40
41 • A scoping review can only provide a broad overview of the existing research.
42
- 43
44 • The lack of standardized terminology for the MCS construct makes identifying and
45 documenting relevant research challenging.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Multiple Chemical Sensitivity (MCS) has been characterized by reported adverse responses to environmental exposures of common chemical agents in low doses considered non-toxic for the general population. These may be solvents such as paint and cleaning products, odorants such as perfume and scented soaps, air pollutants such as cigarette smoke and smog, or materials such as new furnishings or new carpets. Symptoms are nonspecific, involve multiple organ systems, and may include nausea, dizziness, headache, abdominal pain, fatigue, and depression, among others [1-3]. Responses generalize from individual to sets of often unrelated chemical agents and limit social and occupational functioning [2, 4-8]. Terminology varies and some authors describe the condition more broadly as an idiopathic environmental intolerance [2, 9, 10]. Other researchers have called for a paradigm shift, moving away from terms that characterize the symptoms (“sensitivities”) to a more neutral description as *symptoms associated with environmental factors* (SAEF) [11 12].

To date, tens of thousands of publications have addressed MCS in the international lay and scientific literature [13]. However, little consensus exists regarding MCS, including its defining characteristics [14-19]. Prevalence estimates vary considerably, suggesting differences in operationalizations of the definition and diagnostic criteria for MCS [20-23]. Individual symptoms reported by patients are not unique to MCS and the lack of consensus, including whether MCS should be considered a distinct disorder, hinders the identification and differential diagnosis of MCS in clinical practice [24-26]. Much debate centers around the underlying nature of the condition as toxigenic or psychogenic [27-29]. A large number of potentially underlying mechanisms of action for MCS have been described (e.g., immune system dysregulation, neural

1
2
3 sensitization and hyperresponsivity, neurogenic inflammation, limbic system dysfunction,
4
5 oxidative stress hypothesis, genetic theories, and classical conditioning) [5]. Regardless of the
6
7 challenges in operationalizing definitions and establishing its etiology, MCS is an internationally
8
9 recognized phenomenon that has been described in different formats and terms for decades [5]. It
10
11 is a distressing and puzzling condition for patients as well as their healthcare providers [30-32].
12
13 Some hypotheses about mechanisms of action have resulted in proposed interventions for
14
15 patients; however, no comprehensive review of the evaluated treatment and management options
16
17 exists that currently successfully supports patients describing MCS symptoms [33, 34]. Few
18
19 attempts have been made to establish consensus on how patients presenting with MCS should be
20
21 assessed or treated in clinical practice and new guidelines highlight the need for a complex
22
23 multidisciplinary approach [35]. Surveys describe multiple, often not evidence-based treatment
24
25 approaches that have been tried by patients, and the lack of clinical guidance leaves healthcare
26
27 practitioners guessing how to best address MCS in their patients [8, 34, 36, 37].
28
29
30
31
32

33 Despite the large number of publications addressing MCS, there is a lack of research
34
35 syntheses that provide an overview of the existing evidence base on the condition. We believe
36
37 that the existing evidence base needs to be mapped as a first step in order to advance research
38
39 and practice in this complex field. Before trying to establish the most salient case definition of
40
41 MCS or the most plausible underlying mechanism(s) leading to MCS in a systematic review, a
42
43 scoping review should systematically identify, explore, and characterize the existing research
44
45 literature. The proposed work will be based on this type of review. Scoping reviews are
46
47 systematic literature review approaches that explore research fields to capture the volume and
48
49 content of scientific literature that is relevant to guiding questions for the review [38-40]. To
50
51 address the complexity of the topic, it is critical that a comprehensive review cast a wide net,
52
53
54
55
56
57
58
59
60

1
2
3 incorporating research from different disciplines and conceptual positions. Our planned scoping
4 review will use extensive literature searches to map the existing literature. The review will
5 provide an overview of proposed definitions of and diagnostic criteria for MCS, identify
6 prevalence and incidence research, document the body of evidence addressing the question of
7 whether MCS is a distinct disorder, compile a compendium of suggested underlying mechanisms
8 of MCS etiology and processes, and provide an overview of the literature on MCS treatment and
9 management that has been published to date.

10
11
12
13
14
15
16
17
18
19 This scoping review was prospectively registered and will be conducted according to
20 established procedures to provide a systematic and transparent exploration of the literature [41].
21 The findings of the scoping review will be presented as an evidence map. Evidence maps are an
22 evidence synthesis tool that provide a visualization of a large evidence base to provide readers
23 with a concise overview [42 43]. They allow a visual and user friendly research overview
24 suitable for a large and diverse research field, effectively mapping the existing evidence [42, 44-
25 51]. The evidence map will document the presence and absence of research on MCS for the five
26 questions guiding the review in a user-friendly format.

37 38 Guiding Questions

39
40
41 The following review questions will guide the scoping review:

- 42
43
44 • GQ1: How is Multiple Chemical Sensitivity (MCS) defined and which diagnostic criteria
45 have been proposed?
- 46
47 • GQ2: What methods are used to report prevalence and incidence estimates of MCS?
- 48
49 • GQ3: What are the characteristics of the body of scientific evidence that addresses
50 whether MCS is a distinct disorder or syndrome?

- GQ4: What underlying mechanisms for MCS have been proposed in the scientific literature?
- GQ5: Which treatment and management approaches for MCS have been evaluated in empirical research studies?

Review Aim

The review will answer the guiding questions with the identified scientific literature in a user-friendly format. A systematic evidence map will provide a visualization of the existing evidence and research gaps.

Methods and Analysis

The review is registered in the Open Science Framework (OSF) [13]. The scoping review will follow the steps for scoping reviews outlined by Arksey and Malloy: Stage 1: identifying the research question; Stage 2: identifying relevant studies; Stage 3: study selection; Stage 4: charting the data; Stage 5: collating, summarizing and reporting the results. In addition, a consultation exercise to inform and validate findings from the scoping review will be conducted. The planned duration is April 2022 to December 2023. The following outlines the steps in detail. The reporting will follow established guidelines [39, 52].

Search Strategy

We will search the international literature on MCS using different taxonomy and nomenclature. Literature searches will be designed, executed, and documented by an experienced evidence review center librarian. The scoping review addresses multiple aspects of MCS, and the search

1
2
3 strategy covers multiple databases to ensure that all scientific literature relevant to MCS will be
4 identified. The use of multiple sources is a key method to minimize selection bias being
5 introduced into the review. We plan on searching the following databases to obtain a diverse set
6 of citations potentially relevant to MCS from different disciplines:
7
8
9
10
11

- 12 • PubMed (biomedical)
- 13
- 14 • CINAHL (nursing)
- 15
- 16 • Embase (biomedical)
- 17
- 18 • Web of Science (general scientific database)
- 19
- 20 • Scopus (health sciences)
- 21
- 22 • PsycINFO (behavioral and social sciences)
- 23
- 24 • Healthcare Administration Database (public health administration)
- 25
- 26 • Current Contents Connect (multidisciplinary)
- 27
- 28 • BIOSIS Citation Index (life sciences)
- 29
- 30 • Environment Index (environmental research)
- 31
- 32 • Environmental Science Database
- 33
- 34 • HERO (Health & Environmental Research Online)
- 35
- 36 • SciFinder (chemical literature)
- 37
- 38 • Agricultural & Environmental Science Collection (includes AGRICOLA, environmental
39 research)
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47

48 The search strategy is shown in the appendix. Content experts provided input regarding
49 individual search terms and databases.
50

51
52 In addition, our review will be informed by existing comprehensive reviews on the topic [4,
53 12, 16, 17, 24, 35, 53-61]. Reviews will be systematically identified through the systematic
54
55
56
57
58
59
60

1
2
3 review filter in PubMed and the Cochrane Database of Systematic Review (SDSR). We will
4
5 screen the international registry PROSPERO for ongoing efforts that could inform this project
6
7 during the update search period; currently, the registry includes only two ongoing efforts that
8
9 address selected aspects of MCS [62, 63].

12 For individual guiding questions, we will search additional sources, including selected and
13
14 pre-specified grey literature sources. For definitions and diagnostic criteria (GQ1), we will
15
16 search the website of global organizations such as the World Health Organization (WHO).
17
18 Searches for prevalence research (GQ2) will reference-mine existing reviews [5]. We will review
19
20 reports identified in PubMed Health regarding consensus statements on MCS as a distinct
21
22 disorder (GQ3) and regarding published suggested underlying mechanisms (GQ4). For
23
24 intervention studies (GQ5), we will search repositories of practice guidelines including [G-I-N](#)
25
26 [64] and the [ECRI](#)-maintained guideline database.[65] In addition, we will search the U.S. trial
27
28 registry [clinicaltrials.gov](#) [66] and the International Clinical Trials Registry Platform maintained
29
30 by the [WHO](#) [67].

33
34
35 In addition, we will reference-mine relevant reviews and included studies and consult with
36
37 content experts to ensure that all relevant literature has been captured.

41 Eligibility Criteria and Screening

42
43
44 We will use a PICOTSO (population, intervention/exposure, comparator, outcome, timing,
45
46 setting, and other limiter) framework to structure the eligibility criteria. For each guiding
47
48 question, we will determine detailed inclusion and exclusion criteria. The criteria, thus far, are as
49
50 follows:

- 51
52
53
54 • Population:

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Publications reporting definitions (GQ1) and studies reporting on the prevalence and incidence (GQ2) of MCS will be limited to those that explicitly state *multiple chemical sensitivity, chemical intolerance, or idiopathic environmental intolerance* with a reference to *chemical* sensitivities (rather than electromagnetic sensitivity or other conditions not associated with perceived exposure to chemical agents, solvents, odorants, air pollutants, or materials). Publications reporting exclusively on the prevalence of individual sick building syndrome symptoms or electromagnetic hypersensitivity will be excluded.
 - Eligible populations for GQ3 and GQ4 will include those that either state *multiple chemical sensitivity* or those that are characterized by symptoms of idiopathic environmental intolerance or exposure to environmental factors with a reference to chemical agents, solvents, odorants, air pollutants, or materials . Populations will not be restricted to human participants diagnosed with MCS, and will instead include a wide range of research that may contribute to establishing MCS as a diagnosis and exploring relevant underlying mechanisms.
 - GQ5 will be limited to samples of human participants where some participants are characterized by MCS, idiopathic environmental intolerance for chemicals, the equivalent of the ICD-10-CM Code F45.9 (somatoform disorder, unspecified), or studies that report on a subgroup of the patients of interest.
 - Intervention/exposure/independent variable:
 - We will accept definitions of MCS and descriptions that include diagnostic criteria (GQ1).

- Prevalence and incidence measures need to state the criteria of MCS clearly to be eligible (GQ2).
- GQ3 studies assessing whether MCS is a distinct disorder (i.e., distinct from other “physical” disorders or “psychiatric” disorders) need to provide empirical evidence of discriminatory power to support the authors’ conclusions or need to be based on formal expert consensus methods. Opinions of individual authors will not be eligible.
- Eligible publications suggesting underlying mechanisms (GQ4) may include evidence for the onset of MCS or the course of the disease, including TILT (toxicant-induced loss of tolerance describing an initiation and a triggering stage).
- Studies evaluating interventions (GQ5) to prevent, manage, or treat MCS will be eligible. Interventions will not be restricted by the content or treatment approach and may include interventions aiming to avoid triggers, focusing on coping with MCS symptoms, desensitization, or addressing the causes of MCS. In addition, interventions in patients diagnosed with MCS will be eligible regardless of the intervention focus (patient-centered rather than intervention-centered approach). Case studies of individual patients will be included if focused on intervention rather than the natural course of the condition and the description is published in a peer-reviewed scientific journal.
- Comparator: Studies will be eligible regardless of the presence of a comparator.
- Outcome: GQ1 publications will need to provide sufficiently detailed descriptions that can be operationalized as a definition or diagnostic criteria. GQ2 studies will need to report a numerical estimate of the prevalence or incidence of MCS. GQ3 and GQ4 will

1
2
3 not be limited by reported outcomes. GQ5 studies may report on patient health (self or
4 clinician report), physiological or psychosocial measures assessing the effect of the
5 intervention (effectiveness as well as safety indicators); quantitative and qualitative data
6 will be eligible. Studies reporting only on treatment uptake, patient or provider
7 acceptability of treatments, or treatment costs will be excluded.
8
9

- 10 • Timing: GQ1 studies will be included regardless of the publication year (e.g., definitions
11 from the 1980s are eligible). GQ2 studies will be eligible regardless of the timing of the
12 exposure or assessment (e.g., childhood exposure, symptoms tested in adults). GQ3 and
13 GQ4 studies will not be restricted by time of exposure or follow-up, and retrospective,
14 concurrent, and prospective studies will be eligible. GQ5 studies will be included
15 regardless of the intervention duration and follow up.
16
17
- 18 • Setting: Studies will not be restricted by setting and will be drawn from the international
19 literature.
20
21
- 22 • Other limiters: English-language publications disseminated to a wide audience through a
23 scientific journal will be eligible. Studies published in abbreviated form (e.g., conference
24 abstracts) will not be eligible for inclusion.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Systematic reviews and relevant narrative reviews will be retained for reference-mining.

41 Multiple publications on the same study (i.e., studies defined by the included participants) will
42 be consolidated into one study record to ensure that a given study is not counted multiple times
43 regardless of the number of publications reported on the study. The literature flow will be
44 transparently documented in a citation management program.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Inclusion Screening Process

We will use an online database (DistillerSR) designed for literature reviews to screen the search output. The team will design detailed citation and full text screening forms to ensure a transparent, consistent, and unambiguous approach. Citations found to be potentially relevant by at least one reviewer will be obtained as full text. Citations screening will be supported by machine learning algorithms to reduce reviewer errors and bias. All citations excluded by a human reviewer will be screened for relevance by the machine learning algorithm to ensure that no potentially relevant publication has been missed.

Full text screening will apply the detailed eligibility criteria. Training will ensure a shared understanding of all inclusion and exclusion criteria across reviewers. Full text publications will be screened by two independent reviewers and any discrepancies will be resolved through discussion in the review team. Dual screening reduces reviewer bias and errors and is critical for this complex topic. The screening decisions and reasons for exclusion of studies will be tracked in the online database and citation management software. This allows us to reconstruct a detailed literature flow and facilitates the documentation of included and excluded publications. Reasons for exclusion will match the exclusion criteria dimensions to orient the reader. The literature flow will be documented in a flow diagram.

Studies excluded at full text will be documented in the appendix of the review together with a reason for exclusion. We will retain background papers, i.e., papers to cite or reviews to reference-mine. We will report the number of included studies and the number of publications reporting on each study across the review and for each guiding question.

Data Abstraction

The data abstraction will provide a concise overview of the evidence.

For **GQ1** (definitions and diagnostic criteria), we will document the suggested definitions and the approach to establish it. We will document published diagnostic criteria of MCS and for diagnostic accuracy studies, the type (e.g., self-report questionnaire, objective test such as exposure chamber and challenge test) and name of the test will be recorded.

For **GQ2** (prevalence and incidence), we will document the data type (e.g., prevalence or incidence), the method of assessment (e.g., self-report, medical record), and the operationalization of MCS (definition, criteria). We will distinguish general, unselected populations (e.g., students) from targeted samples with potentially increased risk (e.g., Gulf War veterans). For each study, we will record the country, sample size, and year of estimate, and identify any published prospective studies.

For **GQ3** (MCS as a distinct disorder), we will document the aim of the study, the employed study design, and the analytic approach to evaluate MCS as a distinct disorder. We will record the type of research approach used to determine whether MCS should or should not be considered a distinct disorder or syndrome (e.g., establishing a unique biomarker, analyzing symptom clusters, documenting explained variance) [26] and differentiate the use of direct, mechanistic, and parallel evidence by the authors [68-70]. We will abstract the authors' conclusion regarding their conceptual agreement with MCS as a distinct disorder with a differential clinical diagnosis.

For **GQ4** (underlying mechanisms), we will broadly categorize the study type and approach to indicate which aspect of the condition the study addresses (e.g., the general etiology or a specific process such as the mechanism of generalizing across agents) and whether the approach assumes a biological, psychological, or other (e.g., multiple processes) hypothesis. For each study, we will

1
2
3 categorize the suggested mechanisms (e.g., immune system dysregulation, neural sensitization and
4 hyperresponsivity, neurogenic inflammation, limbic system dysfunction, oxidative stress
5 hypothesis, genetic theories, or classical conditioning) [5]. This will involve collating and
6 reviewing all identified mechanisms and establishing a categorization system based on the
7 published literature and identified approaches. We will also establish a compendium of frameworks
8 and diagrams reported by the authors. For this, figures published under a Creative Commons license
9 will be included in the compendium; for all others, the publisher will be contacted to request
10 permission to use the figure.
11
12
13
14
15
16
17
18
19
20

21 **GQ5** (therapy and management for MCS) will collate all identified interventions and
22 broadly categorizing interventions as prevention, management, or treatment. We will document the
23 focus of the intervention (e.g., aiming to alter the course of the condition, coping strategies) together
24 with the broad therapeutic approach (removing triggers from environment, diet, supplements,
25 masks, devices, [off-label] medication, psychological approaches). The categorization system will
26 built on existing reviews and the identified empirical research [26]. We will also abstract the author
27 group, publication year, and country.
28
29
30
31
32
33
34
35
36
37

38 Data will be abstracted by one reviewer and checked by an experienced literature review
39 methodologist. We will export data into tables and figures or data files for further analysis.
40
41
42

43 Consultation Exercise

44
45

46 The last step of the scoping review process will be a consultation exercise. We will ask multi-
47 disciplinary technical experts and stakeholders in MCS research, practice, and advocacy to
48 review the results of the scoping review. These reviewers will not have been involved in the
49 review process and will assess the review *de novo*. Previous experiences have shown that this
50 last step of stakeholder involvement provides invaluable input and adds to the usefulness and
51
52
53
54
55
56
57
58
59
60

1
2
3 validity of the end product [41, 71, 72]. The consultation exercise will be conducted as an online
4
5 survey sent to participants together with the review to elicit structured feedback on the content
6
7 and presentation of the review. The input will contribute to the presentation of the scoping
8
9 review results.
10

11 12 13 Patient and Public Involvement 14

15
16 The planned review was presented at a stakeholder meeting organized by the funding agency that
17
18 included a patient representative. Several stakeholders are also part of the scientific steering
19
20 committee that reviewed this protocol (see acknowledgement section). The results of the review
21
22 will be distributed to stakeholders in a formal consultation exercise as outlined above. This step
23
24 will be instrumental in ensuring a user-friendly presentation of results that is useful to patients
25
26 and the public.
27
28
29
30
31
32
33
34

35 Result Presentation 36 37 38

39 Characteristics of all studies meeting inclusion criteria will be documented in concise evidence
40
41 tables to provide a broad documentation of the underlying evidence base. Findings across studies
42
43 will be documented in an evidence map. This visual and user friendly research overview will
44
45 map the existing evidence on MCS.
46
47

48 The evidence map will use a limited number of dimensions to display the existing
49
50 research. Displaying the evidence as a bubble plot, each bubble in the plot will represent a study
51
52 and the size of the bubble will represent the size of the study. The plot will use the x-axis to
53
54 display existing types of research studies to characterize the evidence base further. The y-axis
55
56
57
58
59
60

1
2
3 can be used to characterize the guiding question addressed by the research. In addition, the shape
4
5 of the bubble and/or shading may represent different study designs and methodological
6
7 characteristics. The optimal display will be selected based on input from the consultation
8
9 exercise.
10

11
12 The tables and figures will be accompanied by a narrative that summarizes the identified
13
14 evidence base. This scoping review and evidence map will provide a broad overview of the
15
16 existing research on MCS. It also aims to facilitate a future systematic review of the literature
17
18 that will answer definitive research questions (e.g., what is the prevalence of MCS and the
19
20 effectiveness of treatments for MCS). Scoping and mapping has become increasingly useful to
21
22 prepare more definitive systematic reviews that answer closed questions, in particular for large
23
24 and controversial topics [42, 43, 48, 52, 73, 74]. The scoping review will provide context and
25
26 information on which topic areas are to date amenable to a formal systematic review of the
27
28 literature. The future systematic review will address a narrower scope of approaches that have
29
30 been identified in this scoping review, assess the quality of evidence for distinct topics of
31
32 interest, and synthesize the evidence.
33
34
35
36

37
38 In addition to documenting the existing evidence base, we will clearly outline gaps in the
39
40 literature identified in this scoping review. The gap presentation will use the scoping review's
41
42 eligibility framework to transparently document existing gaps and future research needs. The gap
43
44 analysis will make concrete recommendations to facilitate future research.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ethics and Dissemination and Data Availability

The scoping review was determined to be exempt from further review by the University of Southern California Institutional Review Board (IRB) review in July 2022 (ID UP-22-00516).

The results of the review will be disseminated through a journal manuscript. Data of the scoping review will be publicly available through an online data repository (SRDR+).

Author Contributions

SH obtained funding; SH, MD, KR, OA, JJ designed the study, SH, MD, MB, JR, AIM, CP screened literature to prepare this manuscript; AnM and DT manage the data; SY conducted the literature searches; all authors contributed conceptually to the work and edited this manuscript.

Competing Interests

None of the authors have any conflicts of interest to declare.

Funding

This work was supported by the Marilyn Brachman Hoffman Foundation [ID 015153-00001].

Acknowledgements

We thank Dori Germolec, Howard Hu, Jon Samet, and Roberta White for their thoughtful comments. We also thank Tatjana Walker at the at the Marilyn Brachman Hoffman Foundation for her feedback and support.

References

1. Consensus on Multiple Chemical Sensitivity. Multiple chemical sensitivity: a 1999 consensus. Arch Environ Health 1999;**54**(3):147-9 doi: 10.1080/00039899909602251[published Online First: Epub Date]].
2. Workshop on Multiple Chemical S, World Health Organization. Programme for the Promotion of Chemical Safety, International Programme for Chemical Safety. Report of the Workshop on Multiple Chemical Sensitivities (MCS), Berlin, Germany, 21-23 February 1996. Geneva: World Health Organization, 1996.
3. Cone JE, Harrison R, Reiter R. Patients with multiple chemical sensitivities: clinical diagnostic subsets among an occupational health clinic population. Occup Med 1987;**2**(4):721-38
4. Driesen L, Patton R, John M. The impact of multiple chemical sensitivity on people's social and occupational functioning; a systematic review of qualitative research studies. J Psychosom Res 2020;**132**:109964 doi: 10.1016/j.jpsychores.2020.109964[published Online First: Epub Date]].
5. Zucco GM, Doty RL. Multiple Chemical Sensitivity. Brain Sci 2021;**12**(1) doi: 10.3390/brainsci12010046[published Online First: Epub Date]].
6. Winder C. Mechanisms of multiple chemical sensitivity. Toxicol Lett 2002;**128**(1-3):85-97 doi: 10.1016/s0378-4274(01)00536-7[published Online First: Epub Date]].
7. Cullen MR. The worker with multiple chemical sensitivities - An overview. Occup. Med.-State Art Rev. 1987;**2**(4):655-61
8. Alameda Cuesta A, Pazos Garcíandía Á, Oter Quintana C, Losa Iglesias ME. Fibromyalgia, Chronic Fatigue Syndrome, and Multiple Chemical Sensitivity: Illness Experiences. Clin Nurs Res 2021;**30**(1):32-41 doi: 10.1177/1054773819838679[published Online First: Epub Date]].
9. American Academy of Allergy Asthma and Immunology (AAAAI) Board of Directors. Idiopathic environmental intolerances. J Allergy Clin Immunol 1999;**103**(1 Pt 1):36-40
10. ACOEM Environmental Medicine Committee. ACOEM position statement. Multiple chemical sensitivities: idiopathic environmental intolerance. College of Occupational and Environmental Medicine. J Occup Environ Med 1999;**41**(11):940-2
11. Van den Bergh O, Brown RJ, Petersen S, Witthöft M. Idiopathic Environmental Intolerance: A Comprehensive Model. Clinical Psychological Science 2017;**5**(3):551-67 doi: 10.1177/2167702617693327[published Online First: Epub Date]].
12. Haanes JV, Nordin S, Hillert L, et al. "Symptoms associated with environmental factors" (SAEF) - Towards a paradigm shift regarding "idiopathic environmental intolerance" and related phenomena. J Psychosom Res 2020;**131**:109955 doi: 10.1016/j.jpsychores.2020.109955[published Online First: Epub Date]].
13. Hempel S, Danz M, Robinson KA, et al. Multiple Chemical Sensitivity. Secondary Multiple Chemical Sensitivity 2022. osf.io/4a3wu

14. Gad SC. Multiple Chemical Sensitivity: A Moderator's Viewpoint. *International Journal of Toxicology* (Taylor & Francis) 1999;**18**(6):379-81 doi: 10.1080/109158199225080[published Online First: Epub Date]].
15. Hyams KC. Developing case definitions for symptom-based conditions: the problem of specificity. *Epidemiol Rev* 1998;**20**(2):148-56 doi: 10.1093/oxfordjournals.epirev.a017977[published Online First: Epub Date]].
16. Kreutzer R. Idiopathic environmental intolerance: case definition issues. *Occup Med* 2000;**15**(3):511-7
17. Lacour M, Zunder T, Schmidtke K, Vaith P, Scheidt C. Multiple chemical sensitivity syndrome (MCS)--suggestions for an extension of the U.S. MCS-case definition. *Int J Hyg Environ Health* 2005;**208**(3):141-51 doi: 10.1016/j.ijheh.2005.01.017[published Online First: Epub Date]].
18. Rossi S. PA. Multiple chemical sensitivity: review of the state of the art in epidemiology, diagnosis, and future perspectives. *J Occup Environ Med* 2018;**60**(2):138-46
19. Sparks PJ, Daniell W, Black DW, et al. Multiple chemical sensitivity syndrome: a clinical perspective. I. Case definition, theories of pathogenesis, and research needs. *J Occup Med* 1994;**36**(7):718-30
20. Heo Y, Kim SH, Lee SK, Kim HA. Factors Contributing to the Self-Reported Prevalence of Multiple Chemical Sensitivity in Public Facility Workers and the General Population of Korea. *J uoeh* 2017;**39**(4):249-58 doi: 10.7888/juoeh.39.249[published Online First: Epub Date]].
21. Cui X, Lu X, Hiura M, et al. Prevalence and interannual changes in multiple chemical sensitivity in Japanese workers. *Environ Health Prev Med* 2014;**19**(3):215-9 doi: 10.1007/s12199-014-0378-6[published Online First: Epub Date]].
22. Kipen HM, Hallman W, Kelly-McNeil K, Fiedler N. Measuring chemical sensitivity prevalence: a questionnaire for population studies. *Am J Public Health* 1995;**85**(4):574-7 doi: 10.2105/ajph.85.4.574[published Online First: Epub Date]].
23. Dupas D, Dagorne MA. [Multiple chemical sensitivity: a diagnosis not to be missed]. *Rev Mal Respir* 2013;**30**(2):99-104 doi: 10.1016/j.rmr.2012.06.016[published Online First: Epub Date]].
24. Dantoft TM, Andersson L, Nordin S, Skovbjerg S. Chemical intolerance. *Curr Rheumatol Rev* 2015;**11**(2):167-84 doi: 10.2174/157339711102150702111101[published Online First: Epub Date]].
25. Herr C, Eikmann T. [Environmental-medical diagnosis and therapy. Hasty diagnosis of unspecified environmental syndromes should be avoided]. *Fortschr Med* 1998;**116**(33):26-9
26. Watanabe M, Tonori H, Aizawa Y. Multiple chemical sensitivity and idiopathic environmental intolerance (part two). *Environ Health Prev Med* 2003;**7**(6):273-82 doi: 10.1007/bf02908886[published Online First: Epub Date]].
27. Regal Ramos RJ. [Can we rule out that fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity are psychosomatic diseases?]. *Semergen* 2015;**41**(7):349-53 doi: 10.1016/j.semereg.2015.04.015[published Online First: Epub Date]].
28. Staudenmayer H. Clinical consequences of the EI/MCS "diagnosis": two paths. *Regul Toxicol Pharmacol* 1996;**24**(1 Pt 2):S96-110 doi: 10.1006/rtp.1996.0084[published Online First: Epub Date]].

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
29. Gots RE. Multiple chemical sensitivities: distinguishing between psychogenic and toxicodynamic. *Regul Toxicol Pharmacol* 1996;**24**(1 Pt 2):S8-15 doi: 10.1006/rtph.1996.0071[published Online First: Epub Date]].
30. Sparks PJ, Daniell W, Black DW, et al. Multiple chemical sensitivity syndrome: a clinical perspective. II. Evaluation, diagnostic testing, treatment, and social considerations. *J Occup Med* 1994;**36**(7):731-7
31. Gibson PR, Lindberg A. Physicians' perceptions and practices regarding patient reports of multiple chemical sensitivity. *ISRN Nurs* 2011;**2011**:838930 doi: 10.5402/2011/838930[published Online First: Epub Date]].
32. Phillips T, Rees T. (In)Visibility Online: The Benefits of Online Patient Forums for People with a Hidden Illness: The Case of Multiple Chemical Sensitivity (MCS). *Med Anthropol Q* 2018;**32**(2):214-32 doi: 10.1111/maq.12397[published Online First: Epub Date]].
33. Ross GH. Treatment options in multiple chemical sensitivity. *Toxicol Ind Health* 1992;**8**(4):87-94
34. Gibson PR, Elms AN, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity. *Environ Health Perspect* 2003;**111**(12):1498-504 doi: 10.1289/ehp.5936[published Online First: Epub Date]].
35. Damiani G, Alessandrini M, Caccamo D, et al. Italian Expert Consensus on Clinical and Therapeutic Management of Multiple Chemical Sensitivity (MCS). *Int J Environ Res Public Health* 2021;**18**(21) doi: 10.3390/ijerph182111294[published Online First: Epub Date]].
36. Skovbjerg S, Johansen JD, Rasmussen A, Thorsen H, Elberling J. General practitioners' experiences with provision of healthcare to patients with self-reported multiple chemical sensitivity. *Scand J Prim Health Care* 2009;**27**(3):148-52 doi: 10.1080/02813430902888355[published Online First: Epub Date]].
37. Rest KM. A survey of AOEC physician practices and attitudes regarding multiple chemical sensitivity. *Toxicol Ind Health* 1992;**8**(4):51-65
38. McGowan J, Straus S, Moher D, et al. Reporting scoping reviews-PRISMA ScR extension. *J Clin Epidemiol* 2020;**123**:177-79 doi: 10.1016/j.jclinepi.2020.03.016[published Online First: Epub Date]].
39. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med* 2018;**169**(7):467-73 doi: 10.7326/M18-0850[published Online First: Epub Date]].
40. Peters MDJ, Marnie C, Colquhoun H, et al. Scoping reviews: reinforcing and advancing the methodology and application. *Syst Rev* 2021;**10**(1):263 doi: 10.1186/s13643-021-01821-3[published Online First: Epub Date]].
41. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International Journal of Social Research Methodology* 2005;**8**(1):19-32
42. Miale-Lye IM, Hempel S, Shanman R, Shekelle PG. What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products. *Syst Rev* 2016;**5**:28 doi: 10.1186/s13643-016-0204-x[published Online First: Epub Date]].
43. Hempel S. *Conducting Your Literature Review*. Washington, DC: American Psychological Association, 2019.

- 1
- 2
- 3
- 4 44. Apaydin EA, Maher AR, Raaen L, et al. The Use of Technology in the Clinical Care of
- 5 Depression: An Evidence Map. *J Clin Psychiatry* 2018;**79**(5) doi:
- 6 10.4088/JCP.18r12118[published Online First: Epub Date]].
- 7 45. Apaydin EA, Partikian A, Rollison J, Baxi S, Fu N, Hempel S. An evidence map of
- 8 treatments for infantile epilepsy. *Epilepsy Res* 2021;**178**:106781 doi:
- 9 10.1016/j.epilepsyres.2021.106781[published Online First: Epub Date]].
- 10 46. Apaydin EA, Richardson AS, Baxi S, et al. An evidence map of randomised controlled trials
- 11 evaluating genetic therapies. *BMJ Evid Based Med* 2020 doi: 10.1136/bmjebm-2020-
- 12 111448[published Online First: Epub Date]].
- 13 47. Bouskill K, Hempel S, Richardson A, et al. Evidence map of ductal carcinoma in situ
- 14 management options. *Menopause* 2019;**26**(11):1250-58 doi:
- 15 10.1097/GME.0000000000001397[published Online First: Epub Date]].
- 16 48. Hempel S, Taylor SL, Solloway MR, et al. Evidence Map of Acupuncture. Washington
- 17 (DC), 2014.
- 18 49. Hilton LG, Marshall NJ, Motala A, et al. Mindfulness meditation for workplace wellness: An
- 19 evidence map. *Work* 2019;**63**(2):205-18 doi: 10.3233/WOR-192922[published Online
- 20 First: Epub Date]].
- 21 50. Maher AR, Apaydin EA, Raaen L, Motala A, Baxi S, Hempel S. The Use of Technology in
- 22 the Clinical Care of Anxiety: An Evidence Map. *Psychiatr Serv* 2021;**72**(2):195-99 doi:
- 23 10.1176/appi.ps.202000178[published Online First: Epub Date]].
- 24 51. Solloway MR, Taylor SL, Shekelle PG, et al. An evidence map of the effect of Tai Chi on
- 25 health outcomes. *Syst Rev* 2016;**5**(1):126 doi: 10.1186/s13643-016-0300-y[published
- 26 Online First: Epub Date]].
- 27 52. Haddaway N, Macura B, Whaley P, Pullin A. ROSES for Systematic Review Protocols.
- 28 Version 1.0: figshare, 2018.
- 29 53. De Luca C, Raskovic D, Pacifico V, Thai JC, Korkina L. The search for reliable biomarkers
- 30 of disease in multiple chemical sensitivity and other environmental intolerances. *Int J*
- 31 *Environ Res Public Health* 2011;**8**(7):2770-97 doi: 10.3390/ijerph8072770[published
- 32 Online First: Epub Date]].
- 33 54. Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivities: A systematic review of
- 34 provocation studies. *J Allergy Clin Immunol* 2006;**118**(6):1257-64 doi:
- 35 10.1016/j.jaci.2006.07.046[published Online First: Epub Date]].
- 36 55. Viziano A, Micarelli A, Pasquantonio G, Della-Morte D, Alessandrini M. Perspectives on
- 37 multisensory perception disruption in idiopathic environmental intolerance: a systematic
- 38 review. *Int Arch Occup Environ Health* 2018;**91**(8):923-35 doi: 10.1007/s00420-018-
- 39 1346-z[published Online First: Epub Date]].
- 40 56. Laura D, Robert P, Mary J. The impact of multiple chemical sensitivity on people's social
- 41 and occupational functioning; a systematic review of qualitative research studies. *Journal*
- 42 *of Psychosomatic Research* 2020;**132** doi: 10.1016/j.jpsychores.2020.109964[published
- 43 Online First: Epub Date]].
- 44 57. Romero Pérez P. A First Urological Approach to the Genitourinary Manifestations of
- 45 Multiple Chemical Sensitivity. Systematic Review. *Arch Esp Urol* 2022;**75**(7):584-611
- 46 doi: 10.56434/j.arch.esp.urol.20227507.87[published Online First: Epub Date]].
- 47 58. Kurt TL. Multiple chemical sensitivities--a syndrome of pseudotoxicity manifest as exposure
- 48 perceived symptoms. *J Toxicol Clin Toxicol* 1995;**33**(2):101-5 doi:
- 49 10.3109/15563659509000457[published Online First: Epub Date]].
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59

- 1
- 2
- 3 59. Sparks PJ. Idiopathic environmental intolerances: overview. *Occup Med* 2000;**15**(3):497-510
- 4 60. Clinical ecology. American College of Physicians. *Ann Intern Med* 1989;**111**(2):168-78
- 5 61. Decker JT, Aarestad D, Elliott W, Lowe C. Chemical sensitivity in the workplace. *Journal of*
- 6 *Social Work in Disability & Rehabilitation* 2002;**1**(4):45-61
- 7 62. Mette Toft, Rukayya Nasir Sani, Danijela Gasevic, Ruth McQuillan, Anne Martin. Multiple
- 8 chemical sensitivity: prevalence, triggers, symptoms, and impact on lifestyle. A
- 9 systematic review of epidemiological studies. 2018
- 10 63. Sunita Vohra, Mohammad Karkhaneh, Salima Punja, Susanne King-Jones, Karin Olson.
- 11 Systematic review of evidence for the effectiveness of mind-body interventions to treat
- 12 Multiple Chemical Sensitivity (MCS). 2017
- 13 64. Guidelines International Network. Welcome to Guidelines International Network. Secondary
- 14 Welcome to Guidelines International Network. <https://g-i-n.net/>.
- 15 65. ECRI. ECRI Guidelines Trust. Secondary ECRI Guidelines Trust.
- 16 <https://www.ecri.org/solutions/ecri-guidelines-trust>.
- 17 66. U.S. National Library of Medicine. ClinicalTrials Homepage. Secondary ClinicalTrials
- 18 Homepage. <https://clinicaltrials.gov/>.
- 19 67. World Health Organization. International Clinical Trials Registry Platform. Secondary
- 20 International Clinical Trials Registry Platform. <https://trialsearch.who.int/>.
- 21 68. Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st
- 22 century: how data integration has changed causal inference in molecular epidemiology.
- 23 *Emerg Themes Epidemiol* 2015;**12**:14 doi: 10.1186/s12982-015-0037-4[published Online
- 24 First: Epub Date]].
- 25 69. Hill AB. The Environment and Disease: Association or Causation? *Proc R Soc Med*
- 26 1965;**58**:295-300
- 27 70. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can
- 28 Bradford Hill's 'guidelines for causation' contribute? *J R Soc Med* 2009;**102**(5):186-94
- 29 doi: 10.1258/jrsm.2009.090020[published Online First: Epub Date]].
- 30 71. Hempel S, Bolshakova M, Turner B, et al. Evidence-Based Quality Improvement: A Scoping
- 31 Review of the Literature. *Journal of General Internal Medicine* in press
- 32 72. Torriani-Pasin C, Demers M, Polese JC, et al. mHealth technologies used to capture walking
- 33 and arm use behavior in adult stroke survivors: a scoping review beyond measurement
- 34 properties. *Disabil. Rehabil.* 2021:1-13 doi: 10.1080/09638288.2021.1953623[published
- 35 Online First: Epub Date]].
- 36 73. United States Environmental Protection Agency (EPA). ORD Staff Handbook for
- 37 Developing IRIS Assessments (Public Comment Draft, Nov. 2020). Secondary ORD
- 38 Staff Handbook for Developing IRIS Assessments (Public Comment Draft, Nov. 2020)
- 39 2020. https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=350086.
- 40 74. Hempel S, Xenakis L, Danz M. Systematic Reviews for Occupational Safety and Health
- 41 Questions: Resources for Evidence Synthesis: RAND Corporation, 2016:102.
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Appendix: Search Strategies

Multiple Chemical Sensitivity Scoping Review Protocol

PubMed

"multiple chemical sensitivity"[MeSH Terms] OR ("multiple"[Title/Abstract] AND "chemical"[Title/Abstract] AND "sensitivity"[Title/Abstract]) OR "multiple chemical sensitivity"[Title/Abstract] OR ("multiple"[Title/Abstract] AND "chemical"[Title/Abstract] AND "sensitivities"[Title/Abstract]) OR "multiple chemical sensitivities"[Title/Abstract] OR "MCS syndrome"[Title/Abstract] OR "chemical intolerance"[Title/Abstract] OR "chemically intolerant"[Title/Abstract] OR "chemical hypersensitivity"[Title/Abstract] OR "chemical AIDS"[Title/Abstract] OR "chemical sensitivity disorder"[Title/Abstract] OR "chemical sensitivity syndromes"[Title/Abstract] OR "chemophobia"[Title/Abstract] OR "environmental chemical odor intolerance"[Title/Abstract] OR "sensitivity to environmental chemicals"[Title/Abstract] OR ("chemical"[Title/Abstract] AND "environmental illness"[Title/Abstract]) OR "chemically induced environmental illnesses"[Title/Abstract] OR "total allergy syndrome"[Title/Abstract] OR "twentieth century disease"[Title/Abstract] OR "20th century disease"[Title/Abstract] OR "building-related illness"[Title/Abstract] OR "toxicant induced loss of tolerance"[Title/Abstract] OR "Toxicant-Induced Loss of Tolerance"[Title/Abstract] OR "mast cell activation syndrome"[Title/Abstract] OR "idiopathic environmental intolerance"[Title/Abstract] OR "idiopathic environmental intolerances"[Title/Abstract] OR "idiopathic environmental illness"[Title/Abstract] OR "symptoms associated with environmental factors"[Title/Abstract]

Limit: English language

Agricultural & Environmental Science Collection

(noft("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome")
OR noft("chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
"chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
"chemophobia") OR noft("environmental chemical odor intolerance" OR "sensitivity to
environmental chemicals" OR ("chemical" AND "environmental illness") OR "chemically
induced environmental illnesses") OR noft("total allergy syndrome") OR noft("twentieth century
disease" OR "20th century disease" OR "building-related illness") OR noft("toxicant induced
loss of tolerance" OR "Toxicant-Induced Loss of Tolerance") OR noft("mast cell activation
syndrome") OR noft("idiopathic environmental intolerance" OR "idiopathic environmental
intolerances" OR "idiopathic environmental illness" OR "symptoms associated with
environmental factors"))

AND

(stype.exact("Scholarly Journals" OR "Other Sources" OR "Reports"))

AND

la.exact("ENG"))

BIOSIS

"multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
(Topic) or "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity"
OR "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes"
OR "chemophobia" (Topic) or "environmental chemical odor intolerance" OR "sensitivity to

1
2
3 environmental chemicals" OR ("chemical" AND "environmental illness") OR "chemically
4 induced environmental illnesses" (Topic) OR "total allergy syndrome" (Topic) OR "twentieth
5 century disease" OR "20th century disease" OR "building-related illness" (Topic) or "toxicant
6 induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" (Topic) OR "mast cell
7 activation syndrome" (Topic) OR "idiopathic environmental intolerance" OR "idiopathic
8 environmental intolerances" OR "idiopathic environmental illness" (Topic) OR "symptoms
9 associated with environmental factors" (Topic)

10
11
12
13
14
15
16
17 AND Article (Document Types)

18
19
20
21
22 AND English (Languages)

23 24 25 26 **CINAHL**

27
28 TI ("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
29 OR "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
30 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
31 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
32 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
33 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
34 century disease" OR "building-related illness" OR "toxicant induced loss of tolerance" OR
35 "Toxicant-Induced Loss of Tolerance" OR "mast cell activation syndrome" OR "idiopathic
36 environmental intolerance" OR "idiopathic environmental intolerances" OR "idiopathic
37 environmental illness") OR SU ("multiple chemical sensitivity" OR "multiple chemical
38 sensitivities" OR "MCS syndrome" OR "chemical intolerance" OR "chemically intolerant" OR
39 "chemical hypersensitivity" OR "chemical AIDS" OR "chemical sensitivity disorder" OR
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 "chemical sensitivity syndromes" OR "chemophobia" OR "environmental chemical odor
4 intolerance" OR "sensitivity to environmental chemicals" OR ("chemical" AND "environmental
5 illness") OR "chemically induced environmental illnesses" OR "total allergy syndrome" OR
6
7
8 "twentieth century disease" OR "20th century disease" OR "building-related illness" OR
9
10
11 "toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" OR "mast cell
12 activation syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
13 intolerances" OR "idiopathic environmental illness") OR AB ("multiple chemical sensitivity"
14 OR "multiple chemical sensitivities" OR "MCS syndrome" OR "chemical intolerance" OR
15
16 "chemically intolerant" OR "chemical hypersensitivity" OR "chemical AIDS" OR "chemical
17 sensitivity disorder" OR "chemical sensitivity syndromes" OR "chemophobia" OR
18
19
20 "environmental chemical odor intolerance" OR "sensitivity to environmental chemicals" OR
21 ("chemical" AND "environmental illness") OR "chemically induced environmental illnesses" OR
22
23
24 "total allergy syndrome" OR "twentieth century disease" OR "20th century disease" OR
25
26
27 "building-related illness" OR "toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of
28 Tolerance" OR "mast cell activation syndrome" OR "idiopathic environmental intolerance" OR
29
30
31 "idiopathic environmental intolerances" OR "idiopathic environmental illness" OR "symptoms
32 associated with environmental factors")

33
34
35
36
37
38
39
40
41
42 AND

43
44 English language

45 46 47 48 49 **Current Contents**

50
51 "multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome" OR
52
53
54 "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
55
56
57
58
59

1
2
3 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
4
5 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
6
7 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
8
9 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
10
11 century disease" OR "building-related illness" OR "toxicant induced loss of tolerance" OR
12
13 "Toxicant-Induced Loss of Tolerance" OR "mast cell activation syndrome" OR "idiopathic
14
15 environmental intolerance" OR "idiopathic environmental intolerances" OR "idiopathic
16
17 environmental illness" (Topic) OR "symptoms associated with environmental factors" (Topic)
18
19
20
21 and
22
23 English (Language)
24
25
26 and
27
28 Article or Review Article or Correction (Document Types)
29
30
31
32

33 **EMBASE**

34
35 ('multiple chemical sensitivity':ti,ab,kw OR 'multiple chemical sensitivities':ti,ab,kw OR 'mcs
36
37 syndrome':ti,ab,kw OR 'chemical intolerance':ti,ab,kw OR 'chemically intolerant':ti,ab,kw OR
38
39 'chemical hypersensitivity':ti,ab,kw OR 'chemical aids':ti,ab,kw OR 'chemical sensitivity
40
41 disorder':ti,ab,kw OR 'chemical sensitivity syndromes':ti,ab,kw OR 'chemophobia':ti,ab,kw OR
42
43 'environmental chemical odor intolerance':ti,ab,kw OR 'sensitivity to environmental
44
45 chemicals':ti,ab,kw OR ('chemical':ti,ab,kw AND 'environmental illness':ti,ab,kw) OR
46
47 'chemically induced environmental illnesses':ti,ab,kw OR 'total allergy syndrome':ti,ab,kw OR
48
49 'twentieth century disease':ti,ab,kw OR '20th century disease':ti,ab,kw OR 'building-related
50
51 illness':ti,ab,kw OR 'toxicant induced loss of tolerance':ti,ab,kw OR 'toxicant-induced loss of
52
53
54
55
56
57
58
59
60

tolerance':ti,ab,kw OR 'mast cell activation syndrome':ti,ab,kw OR 'idiopathic environmental
intolerance':ti,ab,kw OR 'idiopathic environmental intolerances':ti,ab,kw OR 'idiopathic
environmental illness':ti,ab,kw OR symptoms associated with environmental factors':ti,ab,kw)

AND

english:la

AND

('article'/it OR 'review'/it)

Environment Index

TI ("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
OR "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
"chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
"chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
century disease" OR "building-related illness" OR "toxicant induced loss of tolerance" OR
"Toxicant-Induced Loss of Tolerance" OR "mast cell activation syndrome" OR "idiopathic
environmental intolerance" OR "idiopathic environmental intolerances" OR "idiopathic
environmental illness") OR SU ("multiple chemical sensitivity" OR "multiple chemical
sensitivities" OR "MCS syndrome" OR "chemical intolerance" OR "chemically intolerant" OR
"chemical hypersensitivity" OR "chemical AIDS" OR "chemical sensitivity disorder" OR
"chemical sensitivity syndromes" OR "chemophobia" OR "environmental chemical odor
intolerance" OR "sensitivity to environmental chemicals" OR ("chemical" AND "environmental

1
2
3 illness") OR "chemically induced environmental illnesses" OR "total allergy syndrome" OR
4
5 "twentieth century disease" OR "20th century disease" OR "building-related illness" OR
6
7 "toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" OR "mast cell
8
9 activation syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
10
11 intolerances" OR "idiopathic environmental illness") OR AB ("multiple chemical sensitivity"
12
13 OR "multiple chemical sensitivities" OR "MCS syndrome" OR "chemical intolerance" OR
14
15 "chemically intolerant" OR "chemical hypersensitivity" OR "chemical AIDS" OR "chemical
16
17 sensitivity disorder" OR "chemical sensitivity syndromes" OR "chemophobia" OR
18
19 "environmental chemical odor intolerance" OR "sensitivity to environmental chemicals" OR
20
21 ("chemical" AND "environmental illness") OR "chemically induced environmental illnesses" OR
22
23 "total allergy syndrome" OR "twentieth century disease" OR "20th century disease" OR
24
25 "building-related illness" OR "toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of
26
27 Tolerance" OR "mast cell activation syndrome" OR "idiopathic environmental intolerance" OR
28
29 "idiopathic environmental intolerances" OR "idiopathic environmental illness" OR "symptoms
30
31 associated with environmental factors")

32
33
34
35
36
37 AND

38
39 English language

40 41 42 43 44 **Environmental Science**

45
46 (not("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
47
48 OR "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
49
50 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
51
52 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
53
54
55
56
57
58
59
60

1
2
3 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
4
5 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
6
7 century disease" OR "building-related illness" OR "toxicant induced loss of tolerance" OR
8
9 "Toxicant-Induced Loss of Tolerance" OR "mast cell activation syndrome" OR "idiopathic
10
11 environmental intolerance" OR "idiopathic environmental intolerances" OR "idiopathic
12
13 environmental illness" OR "symptoms associated with environmental factors") AND
14
15 stype.exact("Reports" OR "Working Papers" OR "Scholarly Journals") AND la.exact("English"))
16
17 AND stype.exact("Reports" OR "Working Papers" OR "Scholarly Journals")
18
19
20
21 And
22
23 Source Type: Reports, Scholarly Journals, Working Papers
24
25
26 AND
27
28 Language: English
29
30
31
32

33 **Healthcare Administration**

34
35 noft("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome"
36
37 OR "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
38
39 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
40
41 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
42
43 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
44
45 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
46
47 century disease" OR "building-related illness" OR "toxicant induced loss of tolerance" OR
48
49 "Toxicant-Induced Loss of Tolerance" OR "mast cell activation syndrome" OR "idiopathic
50
51
52
53
54
55
56
57
58
59
60

1
2
3 environmental intolerance" OR "idiopathic environmental intolerances" OR "idiopathic
4 environmental illness" OR "symptoms associated with environmental factors")Limits applied

5
6
7
8 AND

9
10 Source type: Reports, Scholarly Journals

11
12 AND

13
14 Language: English

15
16
17
18
19 **HERO**

20
21 "multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome" OR
22 "chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
23 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
24 "chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
25 chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
26 environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
27 century disease" OR "building-related illness" OR "mast cell activation syndrome" OR
28 "idiopathic environmental intolerance" OR "idiopathic environmental intolerances" OR
29 "idiopathic environmental illness" OR "symptoms associated with environmental factors"

30
31
32
33
34
35
36
37
38
39
40
41
42 AND

43
44 Language: English

45
46
47
48
49 **PsycINFO**

50
51 (noft("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome")
52 OR noft("chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
53
54
55
56
57
58
59
60

1
2
3 "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
4
5 "chemophobia") OR noft("environmental chemical odor intolerance" OR "sensitivity to
6
7 environmental chemicals" OR ("chemical" AND "environmental illness") OR "chemically
8
9 induced environmental illnesses") OR noft("total allergy syndrome") OR noft("twentieth century
10
11 disease" OR "20th century disease" OR "building-related illness") OR noft("toxicant induced
12
13 loss of tolerance" OR "Toxicant-Induced Loss of Tolerance") OR noft("mast cell activation
14
15 syndrome") OR noft("idiopathic environmental intolerance" OR "idiopathic environmental
16
17 intolerances" OR "idiopathic environmental illness" OR "symptoms associated with
18
19 environmental factors"))

20
21
22
23
24 AND

25
26 (la.exact("ENG"))

27
28 AND

29
30 stype.exact("Scholarly Journals"))

31 32 33 34 35 **SciFinder**

36
37 "multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "chemical intolerance"
38
39 OR "chemically intolerant" OR "chemical hypersensitivity" OR "chemical AIDS" OR "chemical
40
41 sensitivity disorder" OR "chemical sensitivity syndromes" OR "chemophobia" OR
42
43 "environmental chemical odor intolerance" OR "sensitivity to environmental chemicals" OR
44
45 ("chemical" AND "environmental illness") OR "chemically induced environmental illnesses" OR
46
47 "total allergy syndrome" OR "twentieth century disease" OR "20th century disease" OR
48
49 "building-related illness" OR "toxicant induced loss of tolerance" OR "Toxicant-Induced Loss of
50
51 Tolerance" OR "mast cell activation syndrome" OR "idiopathic environmental intolerance" OR
52
53
54
55
56
57
58
59
60

1
2
3 "idiopathic environmental intolerances" OR "idiopathic environmental illness" OR "symptoms
4 associated with environmental factors"

5
6
7
8 AND

9
10 English language

11
12 AND

13
14 Exclude: Patent, Book, Commentary, Conference, Dissertation, Editorial, Letter

15
16
17
18
19 **SCOPUS**

20
21 (TITLE-ABS-KEY ("multiple chemical sensitivity" OR "multiple chemical sensitivities" OR
22 "MCS syndrome" OR "chemical intolerance" OR "chemically intolerant" OR "chemical
23 hypersensitivity" OR "chemical AIDS" OR "chemical sensitivity disorder" OR "chemical
24 sensitivity syndromes" OR "chemophobia" OR "environmental chemical odor intolerance"
25 OR "sensitivity to environmental chemicals" OR ("chemical" AND "environmental illness")
26 OR "chemically induced environmental illnesses" OR "total allergy syndrome" OR "twentieth
27 century disease" OR "20th century disease" OR "building-related illness" OR "toxicant
28 induced loss of tolerance" OR "Toxicant-Induced Loss of Tolerance" OR "mast cell activation
29 syndrome" OR "idiopathic environmental intolerance" OR "idiopathic environmental
30 intolerances" OR "idiopathic environmental illness" OR "symptoms associated with
31 environmental factors")

32
33
34
35
36
37
38 AND

39
40 (LIMIT-TO (DOCTYPE, "ar") OR LIMIT-TO (DOCTYPE, "re"))

41
42
43
44 AND

45
46 (LIMIT-TO (LANGUAGE, "English"))

Web of Science

"multiple chemical sensitivity" OR "multiple chemical sensitivities" OR "MCS syndrome" OR
"chemical intolerance" OR "chemically intolerant" OR "chemical hypersensitivity" OR
"chemical AIDS" OR "chemical sensitivity disorder" OR "chemical sensitivity syndromes" OR
"chemophobia" OR "environmental chemical odor intolerance" OR "sensitivity to environmental
chemicals" OR ("chemical" AND "environmental illness") OR "chemically induced
environmental illnesses" OR "total allergy syndrome" OR "twentieth century disease" OR "20th
century disease" OR "building-related illness" OR "toxicant induced loss of tolerance" OR
"Toxicant-Induced Loss of Tolerance" OR "mast cell activation syndrome" OR "idiopathic
environmental intolerance" OR "idiopathic environmental intolerances" OR "idiopathic
environmental illness" OR "symptoms associated with environmental factors" (Topic)
AND
English (Language)
AND
Article or Review Article (Document Types)

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review (p 1)
Update	1b	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number (p 7)
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author (p 1, system)
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review (p 17- 18)
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:		
Sources	5a	Indicate sources of financial or other support for the review (p 18)
Sponsor	5b	Provide name for the review funder and/or sponsor (p 18)
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol (p. 18)
INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known (p 4)
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) (p 7)
METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review (p 9-12)
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage (p 7-9)
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated (appendix)
Study records:		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review (p 12-13)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) (p 12)
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators (p 15)
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications (p 13-15)
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale (p 13-15)
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis (N/A)
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised (p 16-17)
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ) (p 16-17)
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) (N/A)
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned (p 16-17)
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) (N/A)
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE) (N/A)

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.